###begin article-title 0
###xml 35 38 35 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Roles of Arrest-Defective Protein 1225 and Hypoxia-Inducible Factor 1alpha in Tumor Growth and Metastasis
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 201 204 201 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 159 165 <span type="species:ncbi:10090">Murine</span>
Vascular endothelial growth factor A (VEGFA), a critical mediator of tumor angiogenesis, is a well-characterized target of hypoxia-inducible factor 1 (HIF-1). Murine arrest-defective protein 1A (mARD1A225) acetylates HIF-1alpha, triggering its degradation, and thus may play a role in decreased expression of VEGFA.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 16 21 16 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 28 31 28 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 166 169 166 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 365 368 365 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 431 434 427 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 565 566 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
###xml 92 97 <span type="species:ncbi:9606">Human</span>
###xml 116 122 <span type="species:ncbi:10090">murine</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
We generated ApcMin/+/mARD1A225 transgenic mice and quantified growth of intestinal polyps. Human gastric MKN74 and murine melanoma B16F10 cells overexpressing mARD1A225 were injected into mice, and tumor growth and metastasis were measured. VEGFA expression and microvessel density in tumors were assessed using immunohistochemistry. To evaluate the role of mARD1A225 acetylation of Lys532 in HIF-1alpha, we injected B16F10-mARD1A225 cell lines stably expressing mutant HIF-1alpha/K532R into mice and measured metastasis. All statistical tests were two-sided, and P values less than .05 were considered statistically significant.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 15 18 15 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 108 113 108 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 171 176 171 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 188 193 188 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 200 203 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 320 321 320 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 454 457 454 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 521 522 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 565 568 565 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 641 642 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 657 662 657 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 682 683 682 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 746 749 742 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 838 841 830 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 843 844 835 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 19 34 <span type="species:ncbi:10090">transgenic mice</span>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 161 166 <span type="species:ncbi:10090">mouse</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 204 219 <span type="species:ncbi:10090">transgenic mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
ApcMin/+/mARD1A225 transgenic mice (n = 25) had statistically significantly fewer intestinal polyps than ApcMin/+ mice (n = 21) (number of intestinal polyps per mouse: ApcMin/+ mice vs ApcMin/+/mARD1A225 transgenic mice, mean = 83.4 vs 38.0 polyps, difference = 45.4 polyps, 95% confidence interval [CI] = 41.8 to 48.6; P < .001). The growth and metastases of transplanted tumors were also statistically significantly reduced in mice injected with mARD1A225-overexpressing cells than in mice injected with control cells (P < .01). Moreover, overexpression of mARD1A225 decreased VEGFA expression and microvessel density in tumor xenografts (P < .04) and ApcMin/+ intestinal polyps (P = .001). Mutation of lysine 532 of HIF-1alpha in B16F10-mARD1A225 cells prevented HIF-1alpha degradation and inhibited the antimetastatic effect of mARD1A225 (P < .001).
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 6 9 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
mARD1A225 may be a novel upstream target that blocks VEGFA expression and tumor-related angiogenesis.
###end p 8
###begin p 9
###xml 0 20 0 20 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="10">CONTEXTS AND CAVEATS</title>
###xml 20 35 20 35 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="11">Prior knowledge</title>
###xml 35 383 35 371 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="12">Angiogenesis plays a central role in tumor growth and is mediated by vascular endothelial growth factor A (VEGFA), which is expressed in many tumor types. VEGFA transcription is initiated by hypoxia-inducible factor 1&#945; (HIF-1&#945;). Arrest-defective protein 1A (ARD1A) induces the degradation of HIF-1&#945;, resulting in lower VEGFA expression.</p>
###xml 20 383 20 371 <sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="11">Prior knowledge</title><p textid="12">Angiogenesis plays a central role in tumor growth and is mediated by vascular endothelial growth factor A (VEGFA), which is expressed in many tumor types. VEGFA transcription is initiated by hypoxia-inducible factor 1&#945; (HIF-1&#945;). Arrest-defective protein 1A (ARD1A) induces the degradation of HIF-1&#945;, resulting in lower VEGFA expression.</p></sec>
###xml 383 395 371 383 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="13">Study design</title>
###xml 395 740 383 720 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="14">Growth and metastasis of intestinal tumors were quantified in transgenic mice expressing murine ARD1A. VEGFA expression and blood vessel proliferation in tumors were assessed in these mice relative to controls. The importance of HIF-1&#945; degradation in suppression of VEGFA expression was tested by mutation of the HIF-1&#945; acetylation site.</p>
###xml 383 740 371 720 <sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="13">Study design</title><p textid="14">Growth and metastasis of intestinal tumors were quantified in transgenic mice expressing murine ARD1A. VEGFA expression and blood vessel proliferation in tumors were assessed in these mice relative to controls. The importance of HIF-1&#945; degradation in suppression of VEGFA expression was tested by mutation of the HIF-1&#945; acetylation site.</p></sec>
###xml 740 752 720 732 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="15">Contribution</title>
###xml 752 1039 732 1015 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="16">Overexpression of ARD1A reduced the number and size of both primary tumors and metastases. In addition, ARD1A had an antiangiogenic effect by decreasing VEGFA expression and blood vessel density in tumors. This effect was inhibited by mutation of a single acetylation site in HIF-1&#945;.</p>
###xml 740 1039 720 1015 <sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="15">Contribution</title><p textid="16">Overexpression of ARD1A reduced the number and size of both primary tumors and metastases. In addition, ARD1A had an antiangiogenic effect by decreasing VEGFA expression and blood vessel density in tumors. This effect was inhibited by mutation of a single acetylation site in HIF-1&#945;.</p></sec>
###xml 1039 1051 1015 1027 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="17">Implications</title>
###xml 1051 1149 1027 1125 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="18">The ARD1A protein may act as a novel antitumorigenic agent by blocking tumor-related angiogenesis.</p>
###xml 1039 1149 1015 1125 <sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="17">Implications</title><p textid="18">The ARD1A protein may act as a novel antitumorigenic agent by blocking tumor-related angiogenesis.</p></sec>
###xml 1149 1160 1125 1136 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="19">Limitations</title>
###xml 1160 1416 1136 1388 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="20">The effects of the mutant HIF-1&#945; did not fully override the increased expression of ARD1A, suggesting that additional targets of ARD1A may be involved in regulating tumor growth. The murine ARD1A isoform has not yet been identified in human cell lines.</p>
###xml 1416 1432 1388 1404 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="21">From the Editors</p>
###xml 1149 1432 1125 1404 <sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="19">Limitations</title><p textid="20">The effects of the mutant HIF-1&#945; did not fully override the increased expression of ARD1A, suggesting that additional targets of ARD1A may be involved in regulating tumor growth. The murine ARD1A isoform has not yet been identified in human cell lines.</p><p textid="21">From the Editors</p></sec>
###xml 0 1432 0 1404 <sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="10">CONTEXTS AND CAVEATS</title><sec><title textid="11">Prior knowledge</title><p textid="12">Angiogenesis plays a central role in tumor growth and is mediated by vascular endothelial growth factor A (VEGFA), which is expressed in many tumor types. VEGFA transcription is initiated by hypoxia-inducible factor 1&#945; (HIF-1&#945;). Arrest-defective protein 1A (ARD1A) induces the degradation of HIF-1&#945;, resulting in lower VEGFA expression.</p></sec><sec><title textid="13">Study design</title><p textid="14">Growth and metastasis of intestinal tumors were quantified in transgenic mice expressing murine ARD1A. VEGFA expression and blood vessel proliferation in tumors were assessed in these mice relative to controls. The importance of HIF-1&#945; degradation in suppression of VEGFA expression was tested by mutation of the HIF-1&#945; acetylation site.</p></sec><sec><title textid="15">Contribution</title><p textid="16">Overexpression of ARD1A reduced the number and size of both primary tumors and metastases. In addition, ARD1A had an antiangiogenic effect by decreasing VEGFA expression and blood vessel density in tumors. This effect was inhibited by mutation of a single acetylation site in HIF-1&#945;.</p></sec><sec><title textid="17">Implications</title><p textid="18">The ARD1A protein may act as a novel antitumorigenic agent by blocking tumor-related angiogenesis.</p></sec><sec><title textid="19">Limitations</title><p textid="20">The effects of the mutant HIF-1&#945; did not fully override the increased expression of ARD1A, suggesting that additional targets of ARD1A may be involved in regulating tumor growth. The murine ARD1A isoform has not yet been identified in human cell lines.</p><p textid="21">From the Editors</p></sec></sec>
###xml 0 1432 0 1404 <boxed-text xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float"><sec><title textid="10">CONTEXTS AND CAVEATS</title><sec><title textid="11">Prior knowledge</title><p textid="12">Angiogenesis plays a central role in tumor growth and is mediated by vascular endothelial growth factor A (VEGFA), which is expressed in many tumor types. VEGFA transcription is initiated by hypoxia-inducible factor 1&#945; (HIF-1&#945;). Arrest-defective protein 1A (ARD1A) induces the degradation of HIF-1&#945;, resulting in lower VEGFA expression.</p></sec><sec><title textid="13">Study design</title><p textid="14">Growth and metastasis of intestinal tumors were quantified in transgenic mice expressing murine ARD1A. VEGFA expression and blood vessel proliferation in tumors were assessed in these mice relative to controls. The importance of HIF-1&#945; degradation in suppression of VEGFA expression was tested by mutation of the HIF-1&#945; acetylation site.</p></sec><sec><title textid="15">Contribution</title><p textid="16">Overexpression of ARD1A reduced the number and size of both primary tumors and metastases. In addition, ARD1A had an antiangiogenic effect by decreasing VEGFA expression and blood vessel density in tumors. This effect was inhibited by mutation of a single acetylation site in HIF-1&#945;.</p></sec><sec><title textid="17">Implications</title><p textid="18">The ARD1A protein may act as a novel antitumorigenic agent by blocking tumor-related angiogenesis.</p></sec><sec><title textid="19">Limitations</title><p textid="20">The effects of the mutant HIF-1&#945; did not fully override the increased expression of ARD1A, suggesting that additional targets of ARD1A may be involved in regulating tumor growth. The murine ARD1A isoform has not yet been identified in human cell lines.</p><p textid="21">From the Editors</p></sec></sec></boxed-text>
###xml 457 472 <span type="species:ncbi:10090">transgenic mice</span>
###xml 484 490 <span type="species:ncbi:10090">murine</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 1347 1353 <span type="species:ncbi:10090">murine</span>
###xml 1399 1404 <span type="species:ncbi:9606">human</span>
CONTEXTS AND CAVEATSPrior knowledgeAngiogenesis plays a central role in tumor growth and is mediated by vascular endothelial growth factor A (VEGFA), which is expressed in many tumor types. VEGFA transcription is initiated by hypoxia-inducible factor 1alpha (HIF-1alpha). Arrest-defective protein 1A (ARD1A) induces the degradation of HIF-1alpha, resulting in lower VEGFA expression.Study designGrowth and metastasis of intestinal tumors were quantified in transgenic mice expressing murine ARD1A. VEGFA expression and blood vessel proliferation in tumors were assessed in these mice relative to controls. The importance of HIF-1alpha degradation in suppression of VEGFA expression was tested by mutation of the HIF-1alpha acetylation site.ContributionOverexpression of ARD1A reduced the number and size of both primary tumors and metastases. In addition, ARD1A had an antiangiogenic effect by decreasing VEGFA expression and blood vessel density in tumors. This effect was inhibited by mutation of a single acetylation site in HIF-1alpha.ImplicationsThe ARD1A protein may act as a novel antitumorigenic agent by blocking tumor-related angiogenesis.LimitationsThe effects of the mutant HIF-1alpha did not fully override the increased expression of ARD1A, suggesting that additional targets of ARD1A may be involved in regulating tumor growth. The murine ARD1A isoform has not yet been identified in human cell lines.From the Editors
###end p 9
###begin title 10
CONTEXTS AND CAVEATS
###end title 10
###begin title 11
Prior knowledge
###end title 11
###begin p 12
Angiogenesis plays a central role in tumor growth and is mediated by vascular endothelial growth factor A (VEGFA), which is expressed in many tumor types. VEGFA transcription is initiated by hypoxia-inducible factor 1alpha (HIF-1alpha). Arrest-defective protein 1A (ARD1A) induces the degradation of HIF-1alpha, resulting in lower VEGFA expression.
###end p 12
###begin title 13
Study design
###end title 13
###begin p 14
###xml 62 77 <span type="species:ncbi:10090">transgenic mice</span>
###xml 89 95 <span type="species:ncbi:10090">murine</span>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
Growth and metastasis of intestinal tumors were quantified in transgenic mice expressing murine ARD1A. VEGFA expression and blood vessel proliferation in tumors were assessed in these mice relative to controls. The importance of HIF-1alpha degradation in suppression of VEGFA expression was tested by mutation of the HIF-1alpha acetylation site.
###end p 14
###begin title 15
Contribution
###end title 15
###begin p 16
Overexpression of ARD1A reduced the number and size of both primary tumors and metastases. In addition, ARD1A had an antiangiogenic effect by decreasing VEGFA expression and blood vessel density in tumors. This effect was inhibited by mutation of a single acetylation site in HIF-1alpha.
###end p 16
###begin title 17
Implications
###end title 17
###begin p 18
The ARD1A protein may act as a novel antitumorigenic agent by blocking tumor-related angiogenesis.
###end p 18
###begin title 19
Limitations
###end title 19
###begin p 20
###xml 187 193 <span type="species:ncbi:10090">murine</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
The effects of the mutant HIF-1alpha did not fully override the increased expression of ARD1A, suggesting that additional targets of ARD1A may be involved in regulating tumor growth. The murine ARD1A isoform has not yet been identified in human cell lines.
###end p 20
###begin p 21
From the Editors
###end p 21
###begin p 22
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 199 202 199 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 499 500 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 501 502 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 101 106 <span type="species:ncbi:4932">yeast</span>
###xml 179 185 <span type="species:ncbi:10090">Murine</span>
Arrest-defective protein 1, homolog A (ARD1A) N-acetyltransferase, which was initially identified in yeast, is involved in the regulation of the cell cycle and sporulation (1-4). Murine ARD1A (mARD1A225) acetylates a lysine residue in the oxygen-dependent degradation domain of hypoxia-inducible factor 1, alpha subunit (HIF-1alpha), which enhances binding to the von Hippel-Lindau tumor suppressor protein (VHL) and promotes the subsequent ubiquitination and proteasomal degradation of HIF-1alpha (5,6).
###end p 22
###begin p 23
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 154 155 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 156 157 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 158 160 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 278 280 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 466 467 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
HIF-1 is a key factor involved in cellular adaptation to hypoxia (7). Under normoxic conditions, HIF-1alpha is posttranslationally modified and degraded (5,8-10). However, during hypoxia, HIF-1alpha is stabilized and interacts with HIF-1beta to form a functional HIF-1 complex (11). Transcriptional targets of HIF-1 include genes that promote angiogenesis and metastasis, most notably, the potent proangiogenic protein, vascular endothelial growth factor A (VEGFA) (7).
###end p 23
###begin p 24
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 351 353 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 401 404 397 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 495 498 491 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 553 556 549 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 322 327 <span type="species:ncbi:9606">human</span>
###xml 510 525 <span type="species:ncbi:10090">transgenic mice</span>
VEGFA modulates endothelial cell proliferation and vascular permeability (12) and is overexpressed in many tumor types (13-17), malignant carcinomas (18), and premalignant lesions (19). For example, a statistically significant positive association has been demonstrated between increased levels of HIF-1alpha and VEGFA in human colorectal carcinomas (18). In this study, we examined the role of mARD1A225 in the regulation of both primary tumor growth and metastatic disease. We generated mARD1A225-expressing transgenic mice to determine whether mARD1A225 plays a physiologically important role in regulating tumor growth via HIF-1alpha and VEGFA.
###end p 24
###begin title 25
Methods
###end title 25
###begin title 26
###xml 22 25 22 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 73 77 <span type="species:ncbi:10090">Mice</span>
Construction of mARD1A225 Expression Vector for Generation of Transgenic Mice
###end title 26
###begin p 27
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 202 205 202 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 278 281 278 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 138 145 <span type="species:ncbi:9031">chicken</span>
###xml 702 708 <span type="species:ncbi:9986">rabbit</span>
Sequences encoding a 9His-HRV2-9Myc tag were fused to full-length mARD1A225 cDNA and cloned into the pCAGGS vector under the control of a chicken beta-actin promoter. To investigate the effect of mARD1A225-9His-9Myc fusion protein, 293T cells were transfected with pCAGGS-mARD1A225-9His-9Myc or mock vector (pCAGGS-9His-9Myc) using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Transfected 293T cells were treated with proteasome inhibitor 10 muM MG132 under hypoxia for 4 hours, after which the cells were harvested and lysed. Then, we performed an acetylation assay of HIF-1alpha using an anti-acetyl lysine antibody and western blot analysis with a rabbit polyclonal anti-HIF-1alpha antibody (1:1000) in whole-cell extract.
###end p 27
###begin title 28
###xml 37 40 37 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 48 53 48 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 75 79 <span type="species:ncbi:10090">Mice</span>
Mouse Models and Generation of mARD1A225 and ApcMin/+/mARD1A225 Transgenic Mice
###end title 28
###begin p 29
###xml 183 188 183 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 104 109 <span type="species:ncbi:9606">Women</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 209 214 <span type="species:ncbi:10090">mouse</span>
###xml 379 388 <span type="species:ncbi:10090">nude mice</span>
###xml 511 515 <span type="species:ncbi:10090">mice</span>
All mouse experiments were approved by the Institutional Animal Care and Use Committees (IACUC) of Ewha Women's University and adhered to the National Research Council Guidelines. ApcMin/+ mice, a spontaneous mouse model of intestinal tumorigenesis with a C57BL/6 background, were purchased from the Jackson Laboratory (Bar Harbor, ME). Eight-week-old male C57BL/6 and BALB/cSlc-nude mice were purchased from the Jackson Laboratory and Japan Shizuoka Laboratory Center, Inc (Shizuoka, Japan), respectively. All mice were maintained in the Ewha Laboratory Animal Genomics Center under specific pathogen-free conditions.
###end p 29
###begin p 30
###xml 419 422 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 543 546 543 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 695 698 695 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 747 752 747 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 770 773 770 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 830 835 830 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 842 845 842 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 907 910 907 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1026 1031 1026 1031 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1122 1126 1122 1126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wild</sup>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 846 861 <span type="species:ncbi:10090">transgenic mice</span>
Purified transgenic construct DNA was microinjected into the fertilized eggs collected from the superovulated C57BL/6 females. Genotyping was performed by polymerase chain reaction (PCR) and confirmed by Southern blot analysis of genomic DNA from the tail tissue of founder mice at 2 weeks of age. Eight founder mice were identified via PCR and Southern blot analysis (data not shown). Among these, expression of mARD1A225-His9-HRV2-Myc9 protein was observed through the germline in three lines (0041, 0043, and 0046). The expression of mARD1A225 protein was higher in major organs of the 0041 and 0043 lines than in those of the 0046 line (see , , available online). To determine whether mARD1A225 is associated with tumorigenesis, we crossed ApcMin/+ males with mARD1A225 transgenic (0041 and 0043 lines) females to generate ApcMin/+/mARD1A225 transgenic mice. The PCR primers used were as follows: mARD1A225-forward, 5'_ GGA ATT CGC CGC CGC GAT GAA CAT_3' and His9-HRV2-Myc9-reverse, 5'_ CAC CAC TAG TGT AAG CCG GG _3'; ApcMin/+-forward, 5'_ TTC CAC TTT GGC ATA AGG C_3' and reverse, 5'_ GCC ATC CCT TCA CGT TAG_3'; Apcwild-forward, 5'_ TTC CAC TTT GGC ATA AGG C_3' and reverse, 5'_ TTC TGA GAA AGA CAG AAG TTA_3'.
###end p 30
###begin title 31
Reagents and Antibodies
###end title 31
###begin p 32
###xml 812 813 808 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 83 89 <span type="species:ncbi:9986">Rabbit</span>
###xml 177 183 <span type="species:ncbi:9986">Rabbit</span>
###xml 241 246 <span type="species:ncbi:10090">mouse</span>
###xml 323 328 <span type="species:ncbi:10090">Mouse</span>
###xml 362 368 <span type="species:ncbi:9986">rabbit</span>
###xml 517 522 <span type="species:ncbi:10090">Mouse</span>
###xml 572 578 <span type="species:ncbi:9986">rabbit</span>
###xml 729 735 <span type="species:ncbi:9986">rabbit</span>
MG132, a proteasome inhibitor, was purchased from Calbiochem (Darmstadt, Germany). Rabbit polyclonal anti-HIF-1alpha antibody was obtained from Cayman Chemical (Ann Arbor, MI). Rabbit polyclonal anti-von Willebrand Factor (vWF) antibody and mouse monoclonal anti-CD34 antibody were purchased from Dako (Glostrup, Denmark). Mouse monoclonal anti-Myc antibody and rabbit polyclonal anti-acetyl lysine antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and Cell Signaling (Beverly, MA), respectively. Mouse monoclonal VEGFA antibody (for Western blot) and rabbit polyclonal VEGFA antibody (for immunohistochemistry) were obtained from Novus Biologicals (Littleton, CO) and Thermo (Fremont, CA), respectively. The rabbit polyclonal antibody against ARD1A was purchased from Dinona (Seoul, Korea) (6).
###end p 32
###begin title 33
Cell Culture and Hypoxic Conditions
###end title 33
###begin p 34
###xml 4 10 <span type="species:ncbi:10090">murine</span>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 163 168 <span type="species:ncbi:9606">human</span>
###xml 409 415 <span type="species:ncbi:9913">bovine</span>
###xml 511 516 <span type="species:ncbi:9606">Human</span>
###xml 673 679 <span type="species:ncbi:9913">bovine</span>
The murine melanoma cell lines B16F1 and B16F10 and human embryonic kidney 293T cells were purchased from the American Type Culture Collection (Manassas, VA). The human gastric cancer cell lines MKN74 and NUGC-3 were obtained from the Korea Cell Line Bank (Seoul, Korea). Those cell lines were maintained in Dulbecco's modified Eagle medium (DMEM) (Gibco/Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Gibco/Invitrogen), 100 U/mL penicillin, and 100 mug/mL streptomycin (Gibco/Invitrogen). Human umbilical vein endothelial cells (HUVECs) were purchased from the American Type Culture Collection and were grown in Medium 199 supplemented with 20% fetal bovine serum, 100 U/mL penicillin, 100 mug/mL streptomycin, 3 ng/mL basic fibroblast growth factor, and 5 U/mL heparin. All cells were maintained at 37degreesC in a 5% carbon dioxide humidified incubator.
###end p 34
###begin p 35
###xml 114 115 114 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 293 294 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 393 394 391 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 32 38 <span type="species:ncbi:10090">murine</span>
###xml 59 64 <span type="species:ncbi:9606">human</span>
To generate hypoxic conditions, murine B16F10 melanoma and human gastric MKN74 tumor cells were incubated in 5% CO2 and 1% O2 balanced with N2 in a hypoxic chamber (Forma Scientific, Marietta, OH). Hypoxia was also induced in B16F10 and MKN74 cell lines by treatment with cobalt chloride (CoCl2; Sigma-Aldrich, St Louis, MO) at a final concentration of 200 muM. Cells treated with 200 muM CoCl2 exhibited induction of HIF-1alpha and VEGFA.
###end p 35
###begin title 36
Construction of Plasmid and Stable Cell Lines
###end title 36
###begin p 37
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 242 245 242 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pvu</italic>
###xml 252 255 252 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa</italic>
###xml 304 305 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 394 397 390 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 540 543 536 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 924 927 920 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1331 1334 1327 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1631 1634 1623 1626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1680 1683 1672 1675 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2101 2104 2084 2087 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2125 2128 2108 2111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 180 184 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Sequences encoding a 9His-HRV2-9Myc tag were fused to full-length mARD1A225 cDNA and cloned into pcDNA3.1/His C (Invitrogen) expressing a neomycin resistance gene. We inserted the SV40 early promoter puromycin resistance gene cassette at the PvuII and ApaI sites of the pcDNA3.1-HIF-1alpha/K532R vector (5). This construct drives the expression of both puromycin resistance genes. Stable mARD1A225-expressing cell lines were generated with B16F1, B16F10, MKN74, and NUGC-3 cells. Those cell lines were transfected with pcDNA3.1/His C-mARD1A225-His9-HRV2-Myc9 vector or empty vector (pcDNA3.1/His C-His9-HRV2-Myc9), as a control, by using Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer's instructions. Transfected cells (B16F10, B16F1, and MKN74) were treated with 2 mg/mL geneticin (Roche, Nutley, NJ) for 3 weeks, after which single geneticin-resistant colonies were selected for expression of mARD1A225 in the B16F10 (clones A#1 and A#2), MKN74 (clones A#3 and A#4), and B16F1 (clones A#5 and A #6) cell lines and expression of pcDNA3.1/His C-9His-HRV2-9Myc in mock cell lines (B16F10-mock, MKN74-mock, and B16F1-mock) as the control. Transfected NUGC-3 cells were cultured for 2 weeks in medium containing 2 mg/mL geneticin, after which the geneticin-resistant cells were selected for expression of mARD1A225(NUGC-3-Ard) and pcDNA3.1/His C-His9-HRV2-Myc9 (NUGC-3-mock) in the NUGC-3 cells. These stable cells were not selected for a single clone and, as such, they formed a population with mixed geneticin-resistant colonies. Stable HIF-1alpha/K532R-expressing cell lines were generated with B16F10-mARD1A225 cells using Lipofectamine 2000. B16F10-mARD1A225 cells and B16F10-mock cells were transfected with pcDNA3.1-HIF-1alpha/K532R-puro vector and empty vector (pcDNA3.1-puro), respectively, by using Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer's instructions. Transfectants were treated with 1 mug/mL puromycin (Sigma-Aldrich) for 2 weeks, after which puromycin-resistant colonies were selected for expression of HIF-1alpha/K532R in B16F10-mARD1A225 (clone B16F10-mARD1A225-HIF-1alpha/K532R) cells and expression of pcDNA3.1-puro in B16F10-mock cells (B16F10-mock-mock), as the control. These stable cells were not selected for a single clone and, as such, they form a mixed population of puromycin-resistant colonies.
###end p 37
###begin title 38
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Western Blot Analysis for mARD1A225, HIF-1alpha, and VEGFA Protein
###end title 38
###begin p 39
###xml 58 61 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 505 508 501 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 1010 1016 <span type="species:ncbi:9986">rabbit</span>
###xml 1045 1050 <span type="species:ncbi:10090">mouse</span>
###xml 1076 1081 <span type="species:ncbi:10090">mouse</span>
###xml 1166 1172 <span type="species:ncbi:9986">rabbit</span>
###xml 1182 1187 <span type="species:ncbi:10090">mouse</span>
###xml 1275 1286 <span type="species:ncbi:3704">horseradish</span>
Murine melanoma B16F10 (B16F10, B16F10-mock, B16F10-mARD1A225 #1, and B16F10-mARD1A225 #2) and human gastric MKN74 (MKN74, MKN74-mock, MKN74-mARD1A225 #3, and MKN74-mARD1A225 #4) tumor cells were exposed to hypoxia for 4 and 6 hours, respectively, which resulted in the induction of HIF-1alpha. All cells were lysed in whole-cell extract buffer (10 mM HEPES, pH 7.9; 400 mM NaCl; 0.1 mM EDTA; 5% glycerol; 1 mM dithiothreitol (DTT); and protease inhibitors). Tumors (derived from mice injected with mARD1A225-overexpressing B16F10 and MKN74 cells) were lysed and homogenized using a MICCRA D-8 homogenizer (Art-moderne Labortechnik, Mullheim-Hugelheim, Germany) in protein extract buffer (20 mM HEPES, pH 7.9; 300 mM NaCl; 10 mM EDTA; 0.1% NP40; 100 mM KCl; and protease inhibitors). Total protein (40 mug) was fractionated on a 10% sodium dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ). The membranes were probed with primary antibodies (rabbit polyclonal anti-HIF-1alpha, mouse monoclonal anti-Myc, and mouse monoclonal anti-VEGFA antibodies at 1:1000), followed by secondary antibodies (anti-rabbit and anti-mouse antibody, respectively, at 1:5000 [Zymed Laboratories, San Diego, CA]) conjugated with horseradish peroxidase. Protein-antibody complexes were detected with the ECL Plus system (Amersham Biosciences). Three independent experiments were performed.
###end p 39
###begin title 40
Immunoprecipitation and In Vivo Acetylation Assay of HIF-1alpha
###end title 40
###begin p 41
###xml 58 61 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
Murine melanoma B16F10 (B16F10, B16F10-mock, B16F10-mARD1A225 #1, and B16F10-mARD1A225 #2) and human gastric MKN74 (MKN74, MKN74-mock, MKN74-mARD1A225 #3, and MKN74-mARD1A225 #4) tumor cells were treated with 10 muM proteasome inhibitor MG132 under hypoxia for 4 and 6 hours, respectively.
###end p 41
###begin p 42
###xml 656 662 <span type="species:ncbi:9986">rabbit</span>
All cells were lysed in whole-cell extract buffer (10 mM HEPES, pH 7.9; 400 mM NaCl; 0.1 mM EDTA; 5% glycerol; 1 mM DTT; and protease inhibitors). Anti-acetyl lysine antibody (1 mug) was added to the lysate, followed by the addition of Protein A agarose (Upstate Biotech, Lake Placid, NY) in TEG reaction buffer (20 mM Tris-HCl at pH 7.4, 1 mM EDTA, 10% glycerol, 1 mM DTT, and 150 mM NaCl), and the mixture was stirred overnight at 4degreesC. Immunoprecipitates were washed in TEG washing buffer (TEG reaction buffer containing 0.1% Triton-X 100) and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis with a rabbit polyclonal anti-HIF-1alpha antibody as previously described. Three independent experiments were performed in duplicates.
###end p 42
###begin title 43
Reverse Transcription-PCR Analysis to Test for VEGFA RNA Expression
###end title 43
###begin p 44
###xml 64 67 64 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Total RNA was extracted from MKN74, MKN74-mock, and MKN74-mARD1A225 cells, which were under hypoxic conditions for 48 hours, using a RNA extraction kit (Invitrogen). Complementary DNA was synthesized from 4 mug of total RNA using an oligo-dT primer. The primers used for PCR were as follows: VEGFA forward, 5' _GAGAATTCGGCCTCCGAAACCATGAACTTTCTGCT_ 3' and reverse, 5'_ GAGCATGCCCTCCTGCCCGGCTCACCGC_ 3'; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) forward, 5'_ ACCACAGTCCATGCCATCAC _3' and reverse, 5'_ TCCACCACCCTGTTGCTGTA_ 3'. Thirty cycles of PCR were performed for amplification of VEGFA and GAPDH, and PCR products were detected with autoradiography. Three independent experiments were performed.
###end p 44
###begin title 45
Quantification of VEGFA Expression by Enzyme-Linked Immunosorbent Assay
###end title 45
###begin p 46
###xml 43 48 43 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 53 58 53 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 186 189 186 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 232 233 232 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 346 349 345 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 371 374 370 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 448 451 447 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 472 475 471 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 510 511 508 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 288 294 <span type="species:ncbi:10090">Murine</span>
###xml 383 388 <span type="species:ncbi:9606">human</span>
###xml 602 607 <span type="species:ncbi:10090">mouse</span>
###xml 612 617 <span type="species:ncbi:9606">human</span>
###xml 889 894 <span type="species:ncbi:10090">mouse</span>
###xml 936 940 <span type="species:ncbi:10090">mice</span>
###xml 995 1000 <span type="species:ncbi:10090">mouse</span>
###xml 1004 1009 <span type="species:ncbi:9606">human</span>
###xml 1225 1231 <span type="species:ncbi:9913">bovine</span>
VEGFA protein levels were quantified in ApcMin/+, ApcMin/+/mARD1A225 transgenic mouse serum (12 mice per group, 110 days old), and in conditioned media (1% serum) from control and mARD1A225-expressing cells after treatment with CoCl2 at a final concentration of 200 muM to mimic hypoxia. Murine melanoma B16F10 (B16F10, B16F10-mock, B16F10-mARD1A225 #1, and B16F10-mARD1A225 #2) and human gastric cancer cells MKN74 (MKN74, MKN74-mock, MKN74-mARD1A225 #3, and MKN74-mARD1A225 #4) were treated with 200 muM CoCl2 for 4 and 48 hours, respectively. VEGFA levels were assayed with a commercially available mouse and human enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. Three independent experiments were performed using conditioned media, each sample in duplicates. Of the three experiments, one experiment was performed for mouse serum with two replicates for each of 12 mice per group. Serial dilutions of a purified recombinant mouse or human VEGFA preparation with a known concentration were used to generate a standard curve. The total protein concentration in each conditioned medium was determined with Bio-Rad (Hercules, CA) protein assay reagent using bovine serum albumin to generate a standard curve.
###end p 46
###begin title 47
Collection of Conditioned Media
###end title 47
###begin p 48
###xml 6 9 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 264 267 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 304 307 304 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 426 429 422 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 89 95 <span type="species:ncbi:9913">bovine</span>
###xml 475 480 <span type="species:ncbi:9606">human</span>
mARD1A225-overexpressing MKN74 stable cell lines were grown in T75 flasks with 10% fetal bovine serum. After seeding, cells were incubated for 24 hours, washed gently with serum-free DMEM medium, and incubated with 4 mL of DMEM. MKN74, MKN74-mock, and MKN74-mARD1A225 (A#3 and A#4) cells and MKN74-mARD1A225 cells transfected with HIF-1alpha/K532R were exposed to hypoxia for 48 hours using hypoxic chamber. Also, MKN74-mARD1A225 cells were treated with 10 ng/mL recombinant human VEGFA protein (Sigma-Aldrich) after hypoxic condition. Conditioned media was collected, filtered, and stored at 4degreesC.
###end p 48
###begin title 49
Tube Formation Assay
###end title 49
###begin p 50
###xml 195 196 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 308 311 301 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 345 348 338 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 426 429 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 389 394 <span type="species:ncbi:9606">human</span>
For the tube formation assay, 48-well plates were coated with cold Matrigel (BD Biosciences, Bedford, MA), which was allowed to polymerize at 37degreesC for 30 minutes. HUVECs were seeded (5 x 104 cells per well) onto Matrigel with 500 muL filtered conditioned medium from MKN74, MKN74-mock, and MKN74-mARD1A225 (A#3 and A#4) cells; MKN74-mARD1A225 cells treated with 10 ng/mL recombinant human VEGFA protein; and MKN74-mARD1A225 cells transfected with HIF-1alpha/K532R. Tube formation was assessed after 6 hours and quantified by determining the number of branching points. Each experiment was performed in three replicates.
###end p 50
###begin title 51
Transwell Migration Assay
###end title 51
###begin p 52
###xml 346 347 344 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
HUVEC migration was performed with the Transwell system (Corning, Inc, Corning, NY), which allows cells to pass through a polycarbonate membrane with a pore size of 8 mum in 24-well plates. The lower surface of the filter was coated with 20 muL of type I collagen (0.5 mg/mL). Cells were detached, counted, and plated at a concentration of 5 x 104 cells per well in the upper chamber with conditioned medium, and the lower chamber was filled with 600 muL of conditioned medium to serve as the chemoattractant. After 6 hours of incubation, migrating cells were counted under microscope. Each experiment was performed in three replicates.
###end p 52
###begin title 53
Tumor Cell Invasion Assay into Matrigel
###end title 53
###begin p 54
###xml 318 319 315 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 676 677 667 668 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 802 808 <span type="species:ncbi:3635">cotton</span>
Invasion assays were performed using the Transwell system (Corning, Inc) with a polycarbonate membrane filter (6.5 mm diameter, 8 mum pore size). The upper surface of the filter was coated with 20 muL of Matrigel (0.3 mg/mL; BD Biosciences) and the lower side with 20 muL of type I collagen (0.5 mg/mL). HUVECs (5 x 104 cells per well) were detached from tissue culture plates, washed, resuspended in conditioned medium, and added to the upper compartment of the invasion chamber. Conditioned media were added to the lower compartment. Conditioned media of MKN74 cells served as a negative control. Matrigel invasion chambers were incubated at 37degreesC for 24 hours in 5% CO2. After incubation, the filter inserts were removed from wells, and cells on the upper side of the filter were removed using cotton swabs. Filters were fixed, mounted, and stained according to the manufacturer's instructions. Cells invading the Matrigel and located on the underside of the filter were counted. Three to five invasion chambers were used per condition. Values calculated were numbers of cells averaged over at least three filters.
###end p 54
###begin title 55
###xml 76 80 <span type="species:ncbi:10090">Mice</span>
Tumor Cell Growth and Morphology and Primary Tumor Growth and Metastasis in Mice
###end title 55
###begin p 56
###xml 89 92 89 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 113 116 113 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 188 191 188 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 213 216 213 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 227 228 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 299 302 299 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 323 326 323 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
Growth curves were determined 3 days after seeding B16F1 (B16F1, B16F1-mock, B16F1-mARD1A225 #5, and B16F1-mARD1A225 #6; 5 x 104 cells per well), B16F10 (B16F10, B16F10-mock, B16F10-mARD1A225 #1, and B16F10-mARD1A225 #2; 5 x 104 cells per well), and MKN74 cell lines (MKN74, MKN74-mock, MKN74-mARD1A225 #3, and MKN74-mARD1A225 #4; 3 x 104 cells per well) in triplicate into 12-well plates. B16F1 and B16F10 cell line sizes were determined by fluorescence-activated cell sorter analysis. Cell morphology was examined by photography.
###end p 56
###begin p 57
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 97 100 97 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 122 125 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 279 280 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 325 328 324 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 349 352 348 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 390 391 389 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 435 438 434 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 732 733 730 731 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 788 789 786 787 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 887 888 885 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 934 937 932 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1182 1183 1179 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1310 1311 1307 1308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1369 1372 1366 1369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1401 1404 1398 1401 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1761 1762 1749 1750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1825 1828 1813 1816 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1850 1853 1838 1841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 528 537 <span type="species:ncbi:10090">nude mice</span>
###xml 745 749 <span type="species:ncbi:10090">Mice</span>
###xml 960 965 <span type="species:ncbi:10090">mouse</span>
###xml 979 983 <span type="species:ncbi:10090">mice</span>
###xml 1021 1025 <span type="species:ncbi:10090">mice</span>
###xml 1052 1057 <span type="species:ncbi:10090">mouse</span>
###xml 1101 1105 <span type="species:ncbi:10090">mice</span>
###xml 1349 1353 <span type="species:ncbi:10090">mice</span>
###xml 1381 1385 <span type="species:ncbi:10090">mice</span>
###xml 1430 1434 <span type="species:ncbi:10090">mice</span>
###xml 1462 1466 <span type="species:ncbi:10090">mice</span>
###xml 1521 1525 <span type="species:ncbi:10090">mice</span>
###xml 1548 1553 <span type="species:ncbi:10090">mouse</span>
###xml 1587 1591 <span type="species:ncbi:10090">mice</span>
###xml 1611 1615 <span type="species:ncbi:10090">Mice</span>
###xml 1879 1884 <span type="species:ncbi:10090">mouse</span>
###xml 1918 1922 <span type="species:ncbi:10090">mice</span>
###xml 1948 1952 <span type="species:ncbi:10090">mice</span>
For tumor growth experiments, a total of 5 x 105 B16F10 cells (B16F10, B16F10-mock, B16F10-mARD1A225 #1, and B16F10-mARD1A225 #2) in 200 muL of 1x phosphate-buffered saline (PBS) (n = 8 mice per group) was injected subcutaneously into C57BL/6 mice. In addition, a total of 2 x 107 MKN74 cells (MKN74, MKN74-mock, MKN74-mARD1A225 #3, and MKN74-mARD1A225 #4; n = 10 mice per group) and 2 x 107 NUGC-3 cells (NUGC-3-mock and NUGC-3-mARD1A225-mix; n = 5 mice per group) in 200 muL of PBS were injected subcutaneously into BALB/cSlc-nude mice. When the major axis of the tumors reached approximately 10 mm in length, tumor measurements were initiated. Tumors were measured every 2-4 days with calipers to estimate the volume (0.5 x width2 x length). Mice with necrotic tumors were killed by CO2 asphyxiation, and tumors were isolated and weighed. For metastasis experiments, a total of 3 x 105 cells (B16F10, B16F10-mock, and B16F10-mARD1A225) in 100 muL of PBS/5% mouse serum (n = 8 mice per group) was injected into C57BL/6 mice via the tail vein. If any mouse in any group began to appear moribund, all mice in the entire experiment were killed together (day 19 after injection) by CO2 asphyxiation, and surface tumor nodules in the lung were counted under a dissecting microscope. In addition, a total of 1 x 106 cells of each of B16F10-mock (n = 40 mice), B16F10-mARD1A225 (n = 31 mice), B16F10-mARD1A225-HIF-1alpha/K532R (n = 11 mice), B16F10-mock-mock (n = 15 mice), and B16F10-mock-HIF-1alpha/K532R cell lines (n = 15 mice) in 100 muL of PBS/5% mouse serum were injected into C57BL/6 mice via the tail vein. Mice were killed 14 days after injection, and surface tumor nodules in the lung were counted under a dissecting microscope. Finally, a total of 5 x 105 cells of B16F10 cell lines (B16F10, B16F10-mock, B16F10-mARD1A225 #1, and B16F10-mARD1A225 #2) in 100 muL of PBS/5% mouse serum were injected into C57BL/6 mice via the tail vein (n = 9 mice per group), and overall survival was monitored.
###end p 57
###begin title 58
Polyp Number Determination
###end title 58
###begin p 59
###xml 52 57 52 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 74 79 74 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 90 105 <span type="species:ncbi:10090">transgenic mice</span>
For macroscopic assessment of adenoma formation, ApcMin/+ (n = 25) and ApcMin/+/mARD1A225 transgenic mice (0041 lines, n = 21; 0043 lines, n = 9) were killed by CO2 asphyxiation at 110 days old (when they exhibited sufficient tumor volume and numbers), and the small intestine and colon were isolated. The small intestine was subdivided into three equal segments (duodenum, jejunum, and ileum), dissected longitudinally, rinsed, spread flat on paper, and photographed with a digital camera. Tumor frequency and size were determined using the image analysis program with a semiautomated reading system, AxioVision (Carl Zeiss, Thornwood, NY).
###end p 59
###begin title 60
Wound Healing Assay
###end title 60
###begin p 61
###xml 53 56 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 74 77 74 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 95 98 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 445 446 435 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 568 571 557 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 726 729 707 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 512 517 <span type="species:ncbi:10090">mouse</span>
###xml 692 697 <span type="species:ncbi:10090">mouse</span>
B16F10 cell lines (B16F10, B16F10-mock, B16F10-mARD1A225 #1, B16F10-mARD1A225 #2, B16F10-mARD1A225-HIF-1alpha/K532R cells, B16F10-mock-mock, and B16F10-mock-HIF-1alpha/K532R cells) were cultured as 80% confluent monolayers and wounded by removing strips 300-500 mum wide across the well with a sterile pipette tip. Wounded monolayers were washed twice to remove nonadherent cells. Thereafter, cells were incubated in the presence of 200 muM CoCl2 for 24 hours. In addition, cells were treated with 3 mug/mL anti-mouse VEGFA antibody (B16F10, B16F10-mock, B16F10-mARD1A225-HIF-1alpha/K532R cells, B16F10-mock-mock, and B16F10-mock-HIF-1alpha/K532R cells; R&D Systems) and 25 ng/mL recombinant mouse VEGFA protein (B16F10-mARD1A225 cells; Sigma-Aldrich) for 24 hours, fixed, and photographed. Three independent experiments were performed, each in duplicates.
###end p 61
###begin title 62
Histology
###end title 62
###begin p 63
###xml 26 31 26 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 36 41 36 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 48 51 48 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 126 129 126 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 52 67 <span type="species:ncbi:10090">transgenic mice</span>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 463 468 <span type="species:ncbi:10090">mouse</span>
###xml 505 511 <span type="species:ncbi:9986">rabbit</span>
###xml 547 553 <span type="species:ncbi:9986">rabbit</span>
###xml 597 603 <span type="species:ncbi:9986">rabbit</span>
###xml 733 744 <span type="species:ncbi:3704">horseradish</span>
Intestinal polyps from ApcMin/+, ApcMin/+/mARD1A225 transgenic mice, and tumor tissues (derived from mice injected with mARD1A225-overexpressing B16F10 and MKN74 cells) were removed, immediately fixed with 10% formalin, embedded in paraffin, and 4-mum sections were stained with hematoxylin and eosin. Sections were deparaffinized in xylene and rehydrated in graded alcohol. Antigen retrieval was performed using sodium citrate buffer. Sections were stained with mouse monoclonal anti-CD34 (1:100; Dako), rabbit polyclonal anti-vWF (1:400; Dako), rabbit polyclonal anti-VEGFA (1:200; Thermo), and rabbit polyclonal anti-ARD1A (1:200; Dinona) antibodies. Following incubation with the respective biotinylated secondary antibodies and horseradish peroxidase avidin D (Vector Laboratories, Burlingame, CA), sections were visualized with the peroxidase substrate kit (DAB; Vector Laboratories), followed by counterstaining with hematoxylin.
###end p 63
###begin title 64
Microvessel Determination
###end title 64
###begin p 65
###xml 56 61 56 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 66 71 66 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 78 81 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 114 117 114 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 82 97 <span type="species:ncbi:10090">transgenic mice</span>
###xml 148 154 <span type="species:ncbi:9986">rabbit</span>
###xml 192 197 <span type="species:ncbi:10090">mouse</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
Microvessels were detected in intestinal polyps from ApcMin/+, ApcMin/+/mARD1A225 transgenic mice, or MKN74-mARD1A225 expressing tumor tissue using rabbit polyclonal anti-vWF (1:400; Dako) or mouse monoclonal anti-CD34 (1:100; Dako) antibodies, respectively. Vessels in four or six high-power fields from each of 4-8 mice per group were scored for quantification.
###end p 65
###begin title 66
Statistical Analysis
###end title 66
###begin p 67
###xml 137 138 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
Data are expressed as means with 95% confidence intervals (CIs). Statistical significance was determined with the two-sided Mann-Whitney U test or a two-way repeated measures analysis of variance (SPSS, version 12.0; Statistical Package for Social Sciences, Chicago, IL), where applicable. Survival of mice was assessed by the Kaplan-Meier method, and the difference in median time to death between groups was compared by log-rank tests (SPSS). All tests were two-sided. P values less than .05 were considered statistically significant.
###end p 67
###begin title 68
Results
###end title 68
###begin title 69
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 98 103 98 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 104 108 <span type="species:ncbi:10090">Mice</span>
Effect of mARD1A225 Overexpression on the Number and Size of Intestinal Polyps and Survival in ApcMin/+ Mice
###end title 69
###begin p 70
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 242 245 242 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 417 420 409 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 544 547 536 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
###xml 548 563 <span type="species:ncbi:10090">transgenic mice</span>
To determine the physiological relevance of mARD1A225, we generated a transgenic mouse containing a C-terminal 9His-9Myc epitope-tagged mARD1A225 transgene driven by the beta-actin promoter (see , , available online). The effect of the mARD1A225-9His-9Myc fusion protein on stability and acetylation of HIF-1alpha was examined in 293T cells via acetylation assays. HIF-1alpha was acetylated in cells expressing mARD1A225-9His-9Myc fusion protein (lane 1) but not in mock cells (lane 2) (see , , available online). Transgene expression in mARD1A225 transgenic mice was confirmed by PCR and Southern blot, and expression in the lung, liver, and colon were established by Western blot with an anti-Myc antibody (see ,  and , available online).
###end p 70
###begin p 71
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 118 121 118 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 201 206 201 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 228 233 228 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 240 243 240 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 561 569 561 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 635 640 635 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 647 650 647 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 699 704 699 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 714 719 714 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 731 736 731 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 743 746 743 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 863 864 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 874 882 874 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 921 924 921 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 989 994 989 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1035 1040 1035 1040 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1047 1050 1047 1050 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1095 1096 1095 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1151 1156 1151 1156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1204 1209 1204 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1216 1219 1216 1219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1261 1262 1261 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1272 1280 1272 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 1504 1507 1504 1507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1565 1570 1565 1570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1577 1580 1577 1580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1605 1606 1605 1606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1652 1657 1652 1657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1664 1667 1664 1667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1808 1809 1808 1809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1850 1855 1850 1855 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1929 1937 1929 1937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 1976 1979 1976 1979 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 122 137 <span type="species:ncbi:10090">transgenic mice</span>
###xml 157 162 <span type="species:ncbi:10090">mouse</span>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 244 259 <span type="species:ncbi:10090">transgenic mice</span>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
###xml 623 628 <span type="species:ncbi:10090">mouse</span>
###xml 651 666 <span type="species:ncbi:10090">transgenic mice</span>
###xml 705 709 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
###xml 747 751 <span type="species:ncbi:10090">mice</span>
###xml 1668 1683 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1856 1860 <span type="species:ncbi:10090">mice</span>
To verify whether an increase of mARD1A225 expression affects tumor initiation and/or progression, we crossbred mARD1A225 transgenic mice with a spontaneous mouse model of intestinal tumorigenesis (ApcMin/+ mice) to generate ApcMin/+/mARD1A225 transgenic mice (see , , available online). At approximately 16 weeks of age, mice were killed and polyp numbers and sizes were measured. Gross inspection of polyps and examination of the small intestine with hematoxylin and eosin staining revealed a statistically significant decrease in both polyp size and number (Figure 1, A and B). The total number of intestinal polyps per mouse in ApcMin/+/mARD1A225 transgenic mice was less than 50% of that in ApcMin/+ mice (ApcMin/+ mice vs ApcMin/+/mARD1A225 mice, mean = 83.4 vs 38.0 polyps, difference = 45.4 polyps, 95% CI = 41.8 to 48.6, n = 25 and n = 21, respectively; P < .001) (Figure 1, B). Notably, overexpression of mARD1A225 was associated with 55% reduction in medium (1-2 mm) polyps (ApcMin/+: mean = 52.3, 95% CI = 45.3 to 59.3; ApcMin/+/mARD1A225: mean = 23.6 polyps, 95% CI = 17.6 to 29.6; P < .001) and 79% reduction in large (>2 mm) polyps (ApcMin/+: mean = 23.1 polyps, 95% CI = 15.6 to 30.6; ApcMin/+/mARD1A225: mean = 4.8 polyps, 95% CI = 2.1 to 6.9; P < .001) (Figure 1, B). Comparison of polyp distribution in different segments of the small intestine (duodenum, jejunum, and ileum) revealed similar reductions in each anatomic region (see , available online). The inhibitory effect of mARD1A225 on intestinal tumorigenesis was confirmed in a second ApcMin/+/mARD1A225 transgenic line (n = 9, P = .03, see , available online). Moreover, ApcMin/+/mARD1A225 transgenic mice (n = 10) displayed a statistically significant survival advantage with a median life span of 171 days (95% CI = 150 to 191, P = .005, log-rank test) compared with ApcMin/+ mice (n = 10) with a median life span of 141 days (95% CI = 131 to 151) (Figure 1, C). These results suggest that mARD1A225 acts as a tumor suppressor in vivo.
###end p 71
###begin p 72
###xml 45 48 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 83 88 83 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 95 96 95 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 121 124 121 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">top</bold>
###xml 162 168 162 168 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bottom</bold>
###xml 217 222 217 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 235 240 235 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 247 250 247 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 314 315 313 314 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 382 387 381 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 419 424 418 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 431 434 430 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 564 574 563 573 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 578 579 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 605 610 604 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 660 661 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 668 669 667 668 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 704 709 703 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 784 794 783 793 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">solid line</bold>
###xml 803 808 802 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 815 818 814 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 896 907 895 906 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dotted line</bold>
###xml 911 912 910 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 938 943 937 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 251 266 <span type="species:ncbi:10090">transgenic mice</span>
###xml 268 270 <span type="species:ncbi:10090">Tg</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
###xml 435 437 <span type="species:ncbi:10090">Tg</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 819 821 <span type="species:ncbi:10090">Tg</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
Effect of transgenic overexpression of mARD1A225 on intestinal tumorigenesis in ApcMin/+ mice. A) Representative images (top) and hematoxylin and eosin staining (bottom) of small intestinal polyps from 16-week-old ApcMin/+ mice and ApcMin/+/mARD1A225 transgenic mice (Tg). Magnification x100. Scale bar = 200 mum. B) Tumor size distribution of polyps in the small intestine from ApcMin/+ mice (n = 21 per group) and ApcMin/+/mARD1A225 Tg (n = 25 per group). Polyps were classified according to size in millimeters. Results are means with 95% confidence intervals (error bars). *P < .001, compared with ApcMin/+ mice, determined with the two-sided Mann-Whitney U test. C) Kaplan-Meier survival plot of ApcMin/+ (mean = 141 days, 95% confidence interval = 131 to 151, n = 10 per group, solid line) and ApcMin/+/mARD1A225 Tg (mean = 170 days, 95% confidence interval = 150 to 191, n = 10 per group, dotted line). *P = .005, compared with ApcMin/+ mice, determined with log-rank tests. All statistical tests were two-sided.
###end p 72
###begin title 73
###xml 63 68 63 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 75 78 75 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 90 94 <span type="species:ncbi:10090">Mice</span>
Effect of Reduced VEGFA Expression on Tumor Angiogenesis in ApcMin/+/mARD1A225 Transgenic Mice
###end title 73
###begin p 74
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 140 143 140 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 145 153 145 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 214 222 214 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 348 353 348 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 360 363 360 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 408 413 408 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 465 470 465 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 516 521 516 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 528 531 528 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 576 577 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 587 595 587 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 617 622 617 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 674 679 674 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 686 689 686 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 739 740 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 750 758 750 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 886 894 886 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 978 983 978 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 990 993 990 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1089 1094 1089 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1133 1138 1133 1138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1184 1189 1184 1189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1196 1199 1196 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1243 1244 1243 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1254 1262 1254 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 1297 1300 1297 1300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1385 1390 1385 1390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 364 379 <span type="species:ncbi:10090">transgenic mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 994 1009 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1095 1099 <span type="species:ncbi:10090">mice</span>
###xml 1139 1143 <span type="species:ncbi:10090">mice</span>
###xml 1391 1395 <span type="species:ncbi:10090">mice</span>
To examine the antiangiogenic effect of mARD1A225 via reduction of VEGFA expression, we immunostained intestinal polyps with the anti-mARD1A225 (Figure 2, A, top row panels, brown stain) and anti-VEGFA antibodies (Figure 2, A, second row panels, brown stain). VEGFA expression was statistically significantly decreased in intestinal polyps from ApcMin/+/mARD1A225 transgenic mice compared with those from ApcMin/+ mice (number of VEGFA-positive cells per field, ApcMin/+ mice: mean = 104.7, 95% CI = 92 to 117.4; ApcMin/+/mARD1A225: mean = 30.9, 95% CI = 23.4 to 38.4, n = 8; P = .001) (Figure 2, B) and in serum (ApcMin/+ mice: mean = 30.2 pg/mL, 95% CI = 23.2 to 37.2; ApcMin/+/mARD1A225: mean = 20.4 pg/mL, 95% CI = 14.8 to 26, n = 12; P = .023) (Figure 2, C). Microvessel density of polyps was quantified by immunostaining with an antibody specific for the endothelial marker, vWF (Figure 2, A, four lower panels). Notably, vWF-positive vessels of intestinal polyps from ApcMin/+/mARD1A225 transgenic mice were statistically significantly reduced compared with those of polyps from ApcMin/+ mice (number of vessels per field, ApcMin/+ mice: mean = 63.8, 95% CI = 53.9 to 73.8; ApcMin/+/mARD1A225: mean = 23.7, 95% CI = 16.5 to 7.2, n = 8; P = .001) (Figure 2, D). The data indicate that mARD1A225 inhibits tumor angiogenesis by reducing VEGFA expression in intestinal polyps of ApcMin/+ mice.
###end p 74
###begin p 75
###xml 45 48 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 158 163 158 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 170 173 170 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 191 192 191 192 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 232 235 232 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 237 244 237 244 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">top row</bold>
###xml 254 264 254 264 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">second row</bold>
###xml 299 308 299 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">third row</bold>
###xml 337 342 337 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 355 360 355 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 367 370 367 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 515 524 514 523 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">third row</bold>
###xml 526 538 525 537 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">yellow boxes</bold>
###xml 573 583 572 582 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">red arrows</bold>
###xml 603 613 602 612 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bottom row</bold>
###xml 656 657 654 655 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 759 769 757 767 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 897 898 895 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 962 967 960 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1039 1040 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 1047 1048 1045 1046 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1105 1110 1103 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1123 1128 1121 1126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1135 1138 1133 1136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1444 1454 1442 1452 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 1522 1523 1520 1521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1580 1585 1578 1583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1645 1646 1643 1644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 1653 1654 1651 1652 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1755 1765 1753 1763 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 1882 1883 1880 1881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1947 1952 1945 1950 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 2024 2025 2022 2023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 174 189 <span type="species:ncbi:10090">transgenic mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 371 386 <span type="species:ncbi:10090">transgenic mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
###xml 968 973 <span type="species:ncbi:10090">mouse</span>
###xml 1068 1073 <span type="species:ncbi:10090">mouse</span>
###xml 1111 1115 <span type="species:ncbi:10090">mice</span>
###xml 1139 1154 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1177 1181 <span type="species:ncbi:10090">mice</span>
###xml 1338 1342 <span type="species:ncbi:10090">mice</span>
###xml 1506 1510 <span type="species:ncbi:10090">mice</span>
###xml 1586 1591 <span type="species:ncbi:10090">mouse</span>
###xml 1834 1838 <span type="species:ncbi:10090">mice</span>
###xml 1953 1958 <span type="species:ncbi:10090">mouse</span>
###xml 2032 2034 <span type="species:ncbi:10090">Tg</span>
###xml 2037 2052 <span type="species:ncbi:10090">transgenic mice</span>
Effect of transgenic overexpression of mARD1A225 on neovascularization and vascular endothelial growth factor A (VEGFA) expression in intestinal polyps in ApcMin/+/mARD1A225 transgenic mice. A) Immunohistochemical analysis of mARD1A225 (top row), VEGFA (second row), and von Willebrand Factor (vWF, third row) in intestinal polyps of ApcMin/+ mice and ApcMin/+/mARD1A225 transgenic mice at 16 weeks of age (n = 8 mice per group). Magnification x200. Scale bars = 100 mum. Higher magnification of the selected area (third row, yellow boxes) on vWF with vessels indicated by red arrows within the polyps (bottom row). Magnification x400. Scale bar = 20 mum. B) The numbers of VEGFA-positive cells in polyps are presented as means with 95% confidence intervals (error bars). VEGFA-positive cells in four high-power fields (x200) from each of the eight mice per group were scored for quantification. *P = .001, compared with the number of VEGFA-positive cells in ApcMin/+ mouse intestinal polyps, as determined with the two-sided Mann-Whitney U test. C) Concentrations of mouse VEGFA protein in serum from ApcMin/+ mice and ApcMin/+/mARD1A225 transgenic mice, respectively (n = 12 mice per group). VEGFA protein levels were quantified by enzyme-linked immunosorbent assay (ELISA). The experiment was performed in two replicate for each of 12 mice per group. The levels of VEGFA protein in serum are presented as means and 95% confidence intervals (error bars) that are derived from the means of the individual mice (n = 12). *P = .023, compared with the levels of VEGFA protein in ApcMin/+ mouse serum, as determined with the two-sided Mann-Whitney U test. D) The numbers of vWF-positive vessels in polyps are presented as means and 95% confidence intervals (error bars). Vessels from five high-power fields (x400) from each of the eight mice per group were scored for quantification. *P = .001, compared with the number of vWF-positive vessels in ApcMin/+ mouse intestinal polyps, as determined with the two-sided Mann-Whitney U test. Tg = transgenic mice.
###end p 75
###begin title 76
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Effect of mARD1A225 on Primary Tumor Growth
###end title 76
###begin p 77
###xml 42 45 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 186 189 186 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 365 368 365 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 136 145 <span type="species:ncbi:10090">nude mice</span>
###xml 201 207 <span type="species:ncbi:10090">murine</span>
###xml 228 233 <span type="species:ncbi:9606">human</span>
To determine the in vivo effects of mARD1A225 expression on primary tumor growth, we used a xenograft tumor model in which syngeneic or nude mice were injected subcutaneously with mARD1A225-expressing murine B16F10 melanoma and human gastric MKN74 tumor cells, respectively. These cell lines were established from single clones expressing different levels of mARD1A225 protein (see , , available online). Clonal cell lines did not display statistically significant differences in proliferation (see , , available online), cell size (see , , available online), or morphological teratism under normoxic conditions (see , , available online).
###end p 77
###begin p 78
###xml 173 176 173 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 193 196 193 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 204 212 204 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 252 255 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 318 319 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 373 374 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 416 419 416 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 440 441 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 483 486 483 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 507 508 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 551 552 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 572 573 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 594 602 594 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 624 627 624 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 699 700 699 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 752 753 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 790 793 790 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 812 813 812 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 850 853 850 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 872 873 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 914 915 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 935 936 935 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 957 965 957 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 1001 1004 1001 1004 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 1064 1069 <span type="species:ncbi:9606">human</span>
Tumors were isolated, weighed, and measured at day 18 (B16F10) or day 20 (MKN74). Tumor growth was statistically significantly suppressed in mice injected with B16F10-mARD1A225 and MKN74-mARD1A225 cells (Figure 3, A and B). At day 18, for B16F10-mARD1A225 cells, tumor volumes were as follows: B16F10, mean = 2989.5 mm2, 95% CI = 1502 to 4477; B16F10/mock, mean = 2851.9 mm2, 95% CI = 2547.1 to 3156.8; B16F10/mARD1A225 #1, mean = 1734.1 mm2, 95% CI = 1053.1 to 2415.2; B16F10/mARD1A225 #2, mean = 1255.4 mm2, 95% CI = 901 to 1609.7 (n = 8 per group, P = .003, clone A#1, P < .001, clone A#2) (Figure 3, A). For MKN74-mARD1A225 cells, at day 20, tumor volumes were as follows: MKN74, mean = 279.7 mm2, 95% CI = 149.4 to 410; MKN74/mock, mean = 330.4 mm2, 95% CI = 237.7 to 423; MKN74/mARD1A225 #3, mean = 60.5 mm2, 95% CI = 38.9 to 82.2; MKN74/mARD1A225 #4, mean = 46.7 mm2, 95% CI = 38 to 55.5 (n = 10 per group, P = .007, clone A#3, P < .001, clone A#4) (Figure 3, B). An inhibitory effect of mARD1A225 on primary tumor growth was additionally observed with the human gastric tumor cell line, NUGC-3 (see , available online).
###end p 78
###begin p 79
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 53 54 53 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 103 113 103 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</bold>
###xml 134 145 134 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right panel</bold>
###xml 213 225 213 225 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">open diamond</bold>
###xml 241 252 241 252 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">open square</bold>
###xml 271 274 271 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 282 308 282 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">two clones; closed symbols</bold>
###xml 359 369 359 369 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 373 374 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 504 505 504 505 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 554 564 554 564 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</bold>
###xml 585 596 585 596 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right panel</bold>
###xml 660 672 660 672 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">open diamond</bold>
###xml 687 698 687 698 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">open square</bold>
###xml 716 719 716 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 727 753 727 753 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">two clones; closed symbols</bold>
###xml 804 814 804 814 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 818 819 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 830 831 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 926 927 926 927 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1043 1046 1043 1046 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1102 1112 1102 1112 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 1116 1117 1116 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1206 1207 1206 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 1214 1215 1214 1215 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1330 1333 1330 1333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1389 1399 1389 1399 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 1403 1404 1403 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1415 1416 1415 1416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1505 1506 1505 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 1531 1534 1531 1534 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1558 1561 1558 1561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1584 1587 1584 1587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1610 1613 1610 1613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 609 618 <span type="species:ncbi:10090">Nude mice</span>
Effect of mARD1A225 on primary tumor growth in mice. A) Representative images of primary tumor masses (left panel) and growth curves (right panel) are shown. C57BL/6 mice were injected subcutaneously with B16F10 (open diamond), B16F10-mock (open square), or B16F10-mARD1A225 cells (two clones; closed symbols). Results are means and 95% confidence intervals (error bars). *P = .003, **P < .001, compared with mock control cells, as determined with two-way repeated measures analysis of variance (ANOVA). B) Representative images of primary tumor masses (left panel) and growth curves (right panel) are shown. Nude mice were injected subcutaneously with MKN74 (open diamond), MKN74-mock (open square), or MKN74-mARD1A225 cells (two clones; closed symbols). Results are means and 95% confidence intervals (error bars). *P = .007, **P < .001, compared with mock control cells, as determined with two-way repeated measures ANOVA. C) Tumor weights (n = 8 per group) were measured 3 weeks after inoculation with B16F10, B16F10-mock, or B16F10-mARD1A225 cells. Results are means and 95% confidence intervals (error bars). *P = .021, compared with mock control cells, as determined with the two-sided Mann-Whitney U test. D) Tumor weights (n = 10 per group) were measured 3 weeks after inoculation with MKN74, MKN74-mock, and MKN74-mARD1A225 cells. Results are means and 95% confidence intervals (error bars). *P = .017, **P = .015, compared with mock control cells, as determined with the two-sided Mann-Whitney U test. A#1= B16F10-mARD1A225 #1; A#2 = B16F10-mARD1A225 #2; A#3 = MKN74-mARD1A225 #3; A#4 = MKN74-mARD1A225 #4.
###end p 79
###begin p 80
###xml 13 16 13 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 196 199 196 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 255 258 255 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 332 340 332 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 369 372 369 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 556 559 556 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 617 620 617 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 667 668 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 688 689 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 710 718 710 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 768 771 768 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
B16F10-mARD1A225 tumor weights were 36% of the weight of control tumors on average (B16F10, mean = 3.02 mg, 95% CI = 1.47 to 4.57; B16F10/mock, mean = 4.13 mg, 95% CI = 3.34 to 4.91; B16F10/mARD1A225 #1, mean = 1.28 mg, 95% CI = 0.4 to 2.16; B16F10/mARD1A225 #2, mean = 1.35 mg, 95% CI = 0.5 to 2.19; P = .021 for all comparisons) (Figure 3, C). Similarly, MKN74-mARD1A225 tumor weights were markedly reduced to less than 8% of control tumors (MKN74, mean = 0.3 mg, 95% CI = 0.161 to 0.439; MKN74/mock, mean = 0.35 mg, 95% CI = 0.252 to 0.448; MKN74/mARD1A225 #3, mean = 0.028 mg, 95% CI = 0.015 to 0.04; MKN74/mARD1A225 #4, mean = 0.018 mg, 95% CI = 0.013 to 0.022; P = .017, clone A#3, P = .015, clone A#4) (Figure 3, D). Taken together, the data suggest that mARD1A225 statistically significantly inhibited the growth of transplanted tumors in vivo.
###end p 80
###begin title 81
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Effect of mARD1A225 on Metastatic Lesions in the Lung
###end title 81
###begin p 82
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 284 287 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 295 303 295 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
###xml 343 346 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 517 520 517 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 822 825 822 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 862 863 862 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 885 888 885 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 923 924 923 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 934 942 934 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
###xml 1018 1021 1018 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1102 1110 1102 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
###xml 1196 1199 1196 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1524 1527 1524 1527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1532 1533 1532 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1596 1599 1596 1599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1604 1605 1604 1605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1672 1680 1672 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
###xml 1732 1735 1732 1735 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 311 315 <span type="species:ncbi:10090">Mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 706 711 <span type="species:ncbi:10090">mouse</span>
###xml 986 990 <span type="species:ncbi:10090">mice</span>
###xml 1150 1154 <span type="species:ncbi:10090">mice</span>
###xml 1299 1303 <span type="species:ncbi:10090">Mice</span>
###xml 1427 1431 <span type="species:ncbi:10090">mice</span>
###xml 1492 1496 <span type="species:ncbi:10090">mice</span>
###xml 1563 1567 <span type="species:ncbi:10090">mice</span>
###xml 1635 1639 <span type="species:ncbi:10090">mice</span>
We determined the effect of mARD1A225 on the incidence of lung nodule formation using an experimental model of metastasis. We evaluated the number of lung nodules present at 3 weeks, following intravenous injection with equal numbers of B16F10 parental, B16F10-mock, and B16F10-mARD1A225 cells (Figure 4, A-C). Mice injected with B16F10-mARD1A225 cells contained few lung nodules, whereas numerous nodules were detected in groups injected with B16F10 parental or B16F10-mock cells. In mice injected with B16F10-mARD1A225 cells, the number of surface tumor nodules was markedly decreased to less than 4% of the number of nodules in mice injected with B16F10 or B16F10-mock cells (number of lung nodules per mouse, B16F10, mean = 181.75, 95% CI = 153.2 to 210.3; B16F10/mock, mean = 95, 95% CI = 62.5 to 127.5; B16F10/mARD1A225 #1, mean = 6.5, 95% CI = 0 to 16.0, P = .006; B16F10/mARD1A225 #2, mean = 5, 95% CI = 0 to 11.5, P = .006) (Figure 4, A). The suppression of lung metastases in mice injected with B16F10-mARD1A225 cells was further confirmed by hematoxylin and eosin staining of lung sections (Figure 4, B). Moreover, the overall survival of mice injected intravenously with B16F10-mARD1A225 cells was statistically significantly longer than those injected with B16F10 or B16F10-mock cells. Mice began to die 11 days after the injection of control cells (B16F10, B16F10-mock). By day 25, 100% mortality was observed in mice with control cells, in contrast to 22% and 44% mortality in mice injected with B16F10/mARD1A225 #1 (P < .001, log-rank test; n = 9 mice per group) and B16F10/mARD1A225 #2 (P = .002, log-rank test; n = 9 mice per group) cells, respectively (Figure 4, C). Thus, it appears that overexpression of mARD1A225 strongly suppresses the growth of metastases.
###end p 82
###begin p 83
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 54 61 54 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A and B</bold>
###xml 146 149 146 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 245 246 245 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 280 284 280 284 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</bold>
###xml 321 326 321 326 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 383 393 383 393 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 463 464 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 608 609 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 616 617 616 617 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 712 713 711 712 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 756 757 754 755 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 935 938 933 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 556 560 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
###xml 797 801 <span type="species:ncbi:10090">mice</span>
Effect of mARD1A225 on lung nodule formation in mice. A and B) C57BL/6 mice were injected intravenously with B16F10, B16F10-mock, or B16F10-mARD1A225 cells. The incidence of lung nodules was determined 19 days after injection (n = 8 per group). A) Representative images of lungs (left). Numbers of surface tumor nodules (right). Results are means and 95% confidence intervals (CIs) (error bars) of two independent experiments performed with four mice per group. *P = .006, compared with the number of surface tumor nodules detected in B16F10-mock-injected mice, as determined with the two-sided Mann-Whitney U test. B) Hematoxylin and eosin staining of 4-mum lung tissue sections excised from mice described in (A). Magnification x50. Scale bar = 500 mum. C) Kaplan-Meier survival plot of C57BL/6 mice injected with B16F10 (mean = 16.7 days, 95% CI = 15.7 to 17.7), B16F10-mock (mean = 18 days, 95% CI = 15.5 to 20.5), or B16F10-mARD1A225 cells (A#1, mean = 23.9 days, 95% CI = 22.5 to 25.3; A#2, mean = 22.7 days, 95% CI = 20.8 to 24.5) (n = 9 per group). Comparisons were made with log-rank tests. All statistical tests were two-sided.
###end p 83
###begin title 84
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Effect of mARD1A225 Overexpression on HIF-1alpha and VEGFA Expression In Vitro
###end title 84
###begin p 85
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 146 149 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 205 208 201 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 297 305 289 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 343 346 335 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
To confirm the effects of mARD1A225 on the stability and acetylation of HIF-1alpha in cancer cell lines, we stably expressed epitope-tagged mARD1A225 cDNA. In B16F10 and MKN74 cells transfected with mARD1A225, a qualitative decrease in endogenous HIF-1alpha expression was evident during hypoxia (Figure 5, A). This inhibitory effect of mARD1A225 on HIF-1alpha expression was also observed in clones derived from B16F1 and NUGC-3 tumor cells (see ,  and , available online).
###end p 85
###begin p 86
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 41 42 41 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 112 113 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 127 128 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 146 149 146 149 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">top</bold>
###xml 179 182 179 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 209 210 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 224 225 224 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 243 249 243 249 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bottom</bold>
###xml 273 276 269 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 386 389 382 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 391 392 387 388 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 432 435 428 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 463 464 459 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 493 494 488 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 521 524 516 519 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">top</bold>
###xml 562 565 557 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 593 594 588 589 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 635 636 629 630 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 663 669 657 663 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bottom</bold>
###xml 837 840 827 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 884 885 874 875 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 922 925 912 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 952 953 942 943 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 968 969 958 959 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1164 1165 1154 1155 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1248 1251 1238 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1286 1287 1276 1277 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1373 1376 1363 1366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1443 1444 1432 1433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1463 1467 1452 1456 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</bold>
###xml 1505 1508 1494 1497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1575 1576 1563 1564 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1597 1602 1585 1590 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 1723 1733 1711 1721 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 1794 1795 1782 1783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1806 1807 1794 1795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1818 1819 1806 1807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1905 1906 1893 1894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
Effect of mARD1A225 on VEGFA expression. A) B16F10, B16F10-mock, and B16F10-mARD1A225 cells were exposed to 1% O2 (4H) or 21% O2 (N) for 4 hours (top). MKN74-mock and MKN74-mARD1A225 cells were exposed to 1% O2 (4H) or 21% O2 (N) for 4 hours (bottom). HIF-1alpha and mARD1A225 protein levels were examined by Western blot analysis. Anti-Myc antibody was used for the detection of mARD1A225. B) B16F10, B16F10-mock, and B16F10-mARD1A225 cells were exposed to 21% O2 (N) or 10 muM MG132 and 1% O2 for 6 hours (6H + MG132) (top). MKN74, MKN74-mock, and MKN74-mARD1A225 cells were exposed to 21% O2 (N) (not shown) or 10 muM MG132 and 1% O2 for 4 hours (4H + MG132) (bottom). Cell lysates were immunoprecipitated with an anti-acetyl lysine antibody and subjected to Western blot analysis with an anti-HIF-1alpha antibody. The level of mARD1A225 was determined using an anti-Myc antibody. C) MKN74, MKN74-mock, and MKN74-mARD1A225 cells were exposed to 1% O2 (48H) or 21% O2 (N) for 48 hours. Reverse transcription-polymerase chain reaction analysis was performed to detect gene expression using specific primers for VEGFA and glyceraldehyde 3-phosphate dehydrogenase. D) VEGFA protein levels were quantified in conditioned media from control and mARD1A225-expressing cells treated with CoCl2 using enzyme-linked immunosorbent assay ELISA. B16F10, B16F10-mock, and B16F10-mARD1A225 cells were cultured in the absence (N) or presence of 200 muM CoCl2 for 4 hours (4H) (left). MKN74, MKN74-mock, and MKN74-mARD1A225 cells were cultured in the absence (N) or presence of 200 muM CoCl2 for 48 hours (48H) (right). Three independent experiments were performed, each in two replicates. Results are means and 95% confidence intervals (error bars) derived from the means of individual experiments (n = 3). *P = .046, **P = .05, ***P = .021, compared with mock control cells, determined with the two-sided Mann-Whitney U test.
###end p 86
###begin p 87
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 296 299 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 316 319 304 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 327 335 315 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 360 363 348 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
To determine whether mARD1A225 acetylates HIF-1alpha in tumor cells, we performed an acetylation assay using an anti-acetyl lysine antibody after treatment with the proteasome inhibitor MG132 to equalize HIF-1alpha protein levels. Acetylation of HIF-1alpha was markedly increased in B16F10-mARD1A225 and MKN74-mARD1A225 cells (Figure 5, B), and in B16F1-mARD1A225 cells (see , , available online), compared with parental or mock-infected tumor cells.
###end p 87
###begin title 88
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Effect of mARD1A225 on VEGFA Expression and Angiogenesis In Vitro
###end title 88
###begin p 89
###xml 208 211 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 273 281 269 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 345 348 341 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 418 426 414 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 431 432 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 748 751 742 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 808 811 802 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1010 1013 1004 1007 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1072 1075 1066 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1127 1135 1121 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 1422 1425 1416 1419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1490 1493 1484 1487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1699 1702 1693 1696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1767 1770 1761 1764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1823 1831 1817 1825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 1878 1881 1872 1875 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1974 1979 <span type="species:ncbi:9606">human</span>
###xml 1984 1989 <span type="species:ncbi:10090">mouse</span>
To determine the functional consequences of HIF-1alpha acetylation, we examined the expression of VEGFA, a known transcriptional target of HIF-1. The VEGFA mRNA level was appreciably decreased in MKN74-mARD1A225 cells during hypoxia compared with that in MKN74-mock cells (Figure 5, C). Moreover, VEGFA protein expression was decreased in mARD1A225-expressing tumor cell-conditioned medium, relative to control cells (Figure 5, D, P </= .05 for all comparisons). For B16F10 cells under normoxic condition, the concentration of VEGFA (in picograms) protein relative to total protein (in nanograms) was as follows: B16F10, mean = 93.75 pg/ng total protein, 95% CI = 81.5 to 106.25; B16F10/mock, mean = 50 pg/ng, 95% CI = 24.53 to 75.47; B16F10/mARD1A225 #1, mean = 2.08 pg/ng, 95% CI = 0 to 6.16; B16F10/mARD1A225 #2, mean = 8.3 pg/ng, 95% CI = 4.22 to 12.38; in the hypoxic condition: B16F10, mean = 470.83 pg/ng, 95% CI = 430 to 511.66; B16F10/mock, mean = 447.91 pg/ng, 95% CI = 401.9 to 493.92; B16F10/mARD1A225 #1, mean = 337.5 pg/ng, 95% CI = 288 to 387; B16F10/mARD1A225 #2, mean = 297.9 pg/ng, 95% CI = 194.85 to 400.95 (Figure 5, D, left panel). In MKN74 cells under normoxic conditions, the concentration of VEGFA (in picograms) relative to total protein (in nanograms) was as follows: MKN74, mean = 2346.6 pg/ng, 95% CI = 2239.2 to 2454.11; MKN74/mock, mean = 2517.7 pg/ng, 95% CI = 2350.1 to 2685.3; MKN74/mARD1A225 #3, mean = 1289.0 pg/ng, 95% CI = 1066.6 to 1311.6; MKN74/mARD1A225 #4, mean = 1652.0 pg/ng, 95% CI = 1608.9 to 1695.2; in the hypoxic condition: MKN74, mean = 3451.7 pg/ng, 95% CI = 3182.9 to 3720.5; MKN74/mock, mean = 3568.2 pg/ng, 95% CI = 3320.3 to 3816.1; MKN74/mARD1A225 #3, mean = 2314.9 pg/ng, 95% CI = 2153.9 to 2475.9; MKN74/mARD1A225 #4, mean = 2696.8 pg/ng, 95% CI = 2426.8 to 2966.7 (Figure 5, D, right panel). The data confirm that mARD1A225 overexpression leads to decreased expression of HIF-1alpha and VEGFA during hypoxia in both human and mouse cancer cell lines by promoting HIF-1alpha acetylation.
###end p 89
###begin p 90
###xml 130 133 130 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 336 339 336 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 371 379 371 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6</xref>
###xml 539 542 539 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 582 590 578 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6</xref>
###xml 827 830 823 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 883 886 879 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 939 942 935 938 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1001 1004 997 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1063 1066 1059 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1130 1133 1122 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1185 1193 1173 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6</xref>
###xml 1361 1364 1349 1352 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1417 1420 1405 1408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1471 1474 1459 1462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1534 1537 1522 1525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1599 1602 1587 1590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1675 1678 1659 1662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1739 1747 1719 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6</xref>
###xml 1917 1920 1897 1900 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1974 1977 1954 1957 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2030 2033 2010 2013 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2095 2098 2075 2078 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2160 2163 2140 2143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2234 2237 2210 2213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2296 2304 2268 2276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6</xref>
###xml 2350 2353 2322 2325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2519 2527 2491 2499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6</xref>
###xml 2534 2535 2506 2507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
As an endothelial mitogen, VEGFA is a potent mediator of vascular permeability. To establish the antiangiogenic activity of mARD1A225, we examined endothelial cell activation in vitro. Capillary tube formation, migration, and invasion of HUVECs into Matrigel were all inhibited by hypoxic-conditioned media that were derived from mARD1A225-expressing MKN74 tumors cells (Figure 6, A). To confirm the specificity of the VEGFA-mediated effect, we added exogenous VEGFA protein to the conditioned media or used media derived from MKN74-mARD1A225 cells overexpressing HIF-1alpha/K532R (Figure 6, A), which enhanced tube formation, migration, and invasion of endothelial cells. The number of tubes formed per field was as follows: MKN74, mean = 35.7, 95% CI = 29.4 to 41.9; MKN74/mock, mean = 35, 95% CI = 30.1 to 39.9; MKN74/mARD1A225 #3, mean = 17.3, 95% CI = 11.8 to 22.9; MKN74/mARD1A225 #4, mean = 18.7, 95% CI = 14.1 to 23.2; MKN74-mARD1A225 #3+VEGFA, mean = 41.0, 95% CI = 36.9 to 45.1; MKN74-mARD1A225 #4+VEGFA, mean = 44.7, 95% CI = 38.0 to 51.3; MKN74-mARD1A225 #3+HIF-1alpha/K532R, mean = 42, 95% CI = 36 to 48; MKN74-mARD1A225 #4+HIF-1alpha/K532R, mean = 41, 95% CI = 35 to 47 (Figure 6, A). The number of migrated cells per field was as follows: MKN74, mean = 278, 95% CI = 263.2 to 292.8; MKN74/mock, mean = 289.7, 95% CI = 265.5 to 313.8; MKN74/mARD1A225 #3, mean = 39.7, 95% CI = 37.1 to 42.3; MKN74/mARD1A225 #4, mean = 31, 95% CI = 26.5 to 35.5; MKN74-mARD1A225 #3+VEGFA, mean = 271.7, 95% CI = 247 to 296.4; MKN74-mARD1A225 #4+VEGFA, mean = 237.7, 95% CI = 198.2 to 277.1; MKN74-mARD1A225 #3+HIF-1alpha/K532R, mean = 219.3, 95% CI = 184.2 to 254.5; MKN74-mARD1A225 #4+HIF-1alpha/K532R, mean = 276.3, 95% CI = 254.6 to 298.1 (Figure 6, B). The number of invasive cells per field was as follows: MKN74, mean = 253.3, 95% CI = 240.6 to 266.1; MKN74/mock, mean = 250.0, 95% CI = 242.1 to 257.9; MKN74/mARD1A225 #3, mean = 104.7, 95% CI = 102.3 to 107; MKN74/mARD1A225 #4, mean = 70.7, 95% CI = 54.7 to 86.7; MKN74-mARD1A225 #3+VEGFA, mean = 263.3, 95% CI = 245.3 to 281.4; MKN74-mARD1A225 #4+VEGFA, mean = 269.7, 95% CI = 256.6 to 282.8; MKN74-mARD1A225 #3+HIF-1alpha/K532R, mean = 256.7, 95% CI = 236.3 to 277; MKN74-mARD1A225 #4+HIF-1alpha/K532R, mean = 271, 95% CI = 256.2 to 285.8 (Figure 6, C). The results strongly suggest that mARD1A225 suppresses angiogenesis by reducing VEGFA expression and inhibits the activation of endothelial cells, preventing capillary tube formation, migration, and invasion (Figure 6, A-C, P = .05 for all comparisons).
###end p 90
###begin p 91
###xml 113 116 109 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 118 119 114 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 279 282 275 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 304 312 300 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">top left</bold>
###xml 330 333 326 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 437 440 433 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 508 519 500 511 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bottom left</bold>
###xml 577 582 568 573 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 678 688 669 679 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 700 701 691 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 756 757 747 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 805 808 796 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 871 872 862 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 879 880 870 871 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 883 887 874 878 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Left</bold>
###xml 1082 1087 1072 1077 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 1183 1193 1173 1183 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 1205 1206 1195 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1261 1262 1251 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1310 1313 1300 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1376 1377 1366 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 1384 1385 1374 1375 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1533 1537 1523 1527 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</bold>
###xml 1589 1594 1578 1583 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 1690 1700 1679 1689 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 1712 1713 1701 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1768 1769 1757 1758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1817 1820 1806 1809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1883 1884 1872 1873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 1909 1912 1898 1901 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1935 1938 1924 1927 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1967 1970 1956 1959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2032 2035 2021 2024 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2097 2100 2086 2089 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2146 2149 2131 2134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 121 126 <span type="species:ncbi:9606">Human</span>
###xml 374 379 <span type="species:ncbi:9606">human</span>
###xml 1987 1992 <span type="species:ncbi:9606">human</span>
###xml 2052 2057 <span type="species:ncbi:9606">human</span>
Effect of VEGFA treatment or HIF-1alpha/K532R overexpression on tube formation, migration, and invasion by mARD1A225. A) Human umbilical vein endothelial cells (HUVECs) were incubated for 6 hours on Matrigel with hypoxic-conditioned media from MKN74, MKN74-mock, and MKN74-mARD1A225 (A#3 and A#4) cells (top left) and MKN74-mARD1A225 cells treated with 10 ng/mL recombinant human VEGFA protein (A#3+VEGFA and A#4+VEGFA), and MKN74-mARD1A225 cells transfected with HIF-1alpha/K532R (A#3+K532R and A#4+K532R) (bottom left). Scale bar = 200 mum. Quantification of tube formation (right). Results are mean of three replicates from one experiment and their 95% confidence intervals (error bars) (n = 3). *P = .05, compared with the number of MKN74-mock cells; #P = .05, compared with the number of MKN74-mARD1A225 #3 or #4 cells, as determined with the two-sided Mann-Whitney U test. B) (Left) HUVECs and conditioned media were added to transwells, and migrating cells were counted. Data are averaged over three independent experiments. Scale bar = 100 mum. Quantification of migration (right). Results are mean of three replicates from one experiment and their 95% confidence intervals (error bars) (n = 3). *P = .05, compared with the number of MKN74-mock cells; #P = .05, compared with the number of MKN74-mARD1A225 #3 or #4 cells, as determined with the two-sided Mann-Whitney U test. C) Transwells were coated with Matrigel. Cells were stained with hematoxylin and eosin. Representative microscopic images illustrate HUVEC invasion (left). Scale bar = 100 mum. Quantification of invasion (right). Results are mean of three replicates from one experiment and their 95% confidence intervals (error bars) (n = 3). *P = .05, compared with the number of MKN74-mock cells; #P = .05, compared with the number of MKN74-mARD1A225 #3 or #4 cells, as determined with the two-sided Mann-Whitney U test. A#3 = MKN74-mARD1A225 #3; A#4 = MKN74-mARD1A225 #4; A#3+VEGFA = MKN74-mARD1A225 #3+ recombinant human VEGFA protein; A#4+VEGFA = MKN74-mARD1A225 #4+ recombinant human VEGFA protein; A#3+K532R = MKN74-mARD1A225 #3+HIF-1alpha/K532R; A#4+K532R = MKN74-mARD1A225 #4+HIF-1alpha/K532R.
###end p 91
###begin title 92
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Effect of mARD1A225 on HIF-1alpha Degradation and Neovascularization
###end title 92
###begin p 93
###xml 70 73 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 161 162 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 208 210 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 249 252 245 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 414 422 406 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7</xref>
###xml 489 492 481 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 585 593 577 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7</xref>
###xml 831 834 823 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1091 1094 1083 1086 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1133 1134 1125 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1155 1158 1147 1150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1196 1197 1188 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1207 1215 1199 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7</xref>
###xml 1252 1255 1244 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
To determine whether HIF-1alpha and VEGFA levels are reduced in mARD1A225-expressing tumors, we analyzed expression of these proteins in tumors larger than 50 mm2 and thus likely to be hypoxic in the center (20). Tumors that were derived from mARD1A225-expressing B16F10 and MNK74 cells displayed a qualitative decrease in endogenous HIF-1alpha and VEGFA expression compared with parental and mock-infected cells (Figure 7, A and B). Similarly, immunohistochemical staining of MKN74-mARD1A225-expressing tumors displayed lower VEGFA expression than control tumors (MKN74, MKN74-mock) (Figure 7, C). To determine whether microvessel density was associated with VEGFA levels, we used an anti-CD34 antibody to identify endothelial cells and quantify the number of microvessels in these tumors. CD34 staining revealed that MKN74-mARD1A225-expressing tumors displayed lower microvessel density than those derived from mice injected with MKN74 or MKN74-mock cells (number of vessels per field: MKN74, mean = 28.2, 95% CI = 20.6 to 35.7; MKN74/mock, mean = 20.6, 95% CI = 16.6 to 24.5; MKN74/mARD1A225 #3, mean = 12.8, 95% CI = 9.6 to 15.9 P = .043; MKN74/mARD1A225 #4, mean = 2.3, 95% CI = 1.0 to 3.6, P = .021) (Figure 7, D). These data indicate that mARD1A225 inhibits tumor growth and angiogenesis by repressing VEGFA activity through degradation of its upstream regulator, HIF-1alpha.
###end p 93
###begin p 94
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 43 44 43 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 92 95 88 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 139 143 135 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</bold>
###xml 156 161 152 157 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 176 177 172 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 253 257 249 253 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</bold>
###xml 270 275 266 271 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 290 291 286 287 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 385 388 381 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 538 549 534 545 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">brown color</bold>
###xml 643 646 638 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 669 672 664 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 734 735 729 730 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 824 827 819 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 868 872 863 867 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</bold>
###xml 927 932 922 927 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 983 993 978 988 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 1101 1102 1096 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1113 1114 1108 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1260 1261 1255 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 303 312 <span type="species:ncbi:10090">nude mice</span>
###xml 473 478 <span type="species:ncbi:10090">mouse</span>
Effect of mARD1A225 on neovascularization. A) Western blot analysis of HIF-1alpha and mARD1A225 protein expression in transplanted B16F10 (left) and MNK74 (right) tumor cells. B) Western blot analysis of VEGFA protein expression in transplanted B16F10 (left) and MNK74 (right) tumor cells. C) BALB/cSlc-nude mice were injected subcutaneously with MKN74, MKN74-mock, or two MKN74-mARD1A225 clones, A#3 and A#4. After 3 weeks, formalin-fixed primary tumor sections from each mouse were prepared and stained with an anti-VEGFA antibody. The brown color signifies VEGFA in primary tumors. Magnification x400. Scale bar = 50 mum. A#3 = MKN74-mARD1A225 #3; A#4 = MKN74-mARD1A225 #4. One representative image of five per cell line is shown. D) Anti-CD34 staining of xenograft tumors derived from MKN74, MKN74-mock, and MKN74-mARD1A225 cells, indicative of endothelial cells (left). Numbers of CD34-positive vessels in primary tumors (right) expressed as means and 95% confidence intervals (error bars). Vessels from four or five fields from each of the five tumors per group were scored for quantification. *P = .043, **P = .021, compared with the number of CD34-positive vessels in tumors derived from MKN74-mock cells, as determined with the two-sided Mann-Whitney U test. Magnification x200. Scale bar = 100 mum.
###end p 94
###begin title 95
###xml 70 73 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Identification of the Critical Lysine Residue in HIF-1alpha for mARD1A225-Mediated Degradation
###end title 95
###begin p 96
###xml 80 83 76 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 136 137 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 335 338 319 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 359 362 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 497 500 469 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 601 604 569 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 681 689 645 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8</xref>
Previous studies reported that acetylation of lysine 532 of HIF-1alpha by mARD1A225 leads to HIF-1alpha ubiquitination and degradation (5). To determine whether lysine 532 is necessary and sufficient for HIF-1alpha degradation, we mutated this residue and generated cell lines stably expressing mutant HIF-1alpha/K532R in B16F10-mARD1A225 cells (B16F10-mARD1A225-HIF-1alpha/K532R). Examination of HIF-1alpha expression and acetylation after 24 hours of hypoxia revealed HIF-1alpha levels in mARD1A225-HIF-1alpha/K532R to be comparable to those in mock-infected tumor cell lines, suggesting that mARD1A225 is unable to acetylate and degrade HIF-1alpha in the absence of lysine 532 (Figure 8, A).
###end p 96
###begin p 97
###xml 46 47 42 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 143 146 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 165 168 157 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 252 253 239 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 340 341 327 328 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 477 480 464 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 499 502 486 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 586 587 568 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 724 734 706 716 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 799 800 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 873 874 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 881 882 863 864 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 918 921 900 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 940 943 922 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1162 1163 1139 1140 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1216 1219 1193 1196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1310 1313 1282 1285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1406 1410 1378 1382 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</bold>
###xml 1447 1452 1419 1424 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 1492 1493 1464 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1545 1546 1517 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 1671 1681 1643 1653 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 1786 1787 1757 1758 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1875 1878 1846 1849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1910 1913 1881 1884 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2062 2066 2029 2033 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</bold>
###xml 2113 2118 2080 2085 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</bold>
###xml 2169 2179 2136 2146 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">error bars</bold>
###xml 2183 2184 2150 2151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2274 2275 2241 2242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2350 2353 2317 2320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2415 2416 2382 2383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 2442 2445 2409 2412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2469 2472 2436 2439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2506 2509 2473 2476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2692 2695 2655 2658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2770 2773 2729 2732 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 2837 2840 2796 2799 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1275 1280 <span type="species:ncbi:10090">mouse</span>
###xml 1359 1364 <span type="species:ncbi:10090">mouse</span>
###xml 1797 1801 <span type="species:ncbi:10090">mice</span>
###xml 1855 1859 <span type="species:ncbi:10090">mice</span>
###xml 1887 1891 <span type="species:ncbi:10090">mice</span>
###xml 1945 1949 <span type="species:ncbi:10090">mice</span>
###xml 2106 2111 <span type="species:ncbi:10090">mouse</span>
###xml 2267 2271 <span type="species:ncbi:10090">mice</span>
###xml 2363 2367 <span type="species:ncbi:10090">mice</span>
###xml 2567 2572 <span type="species:ncbi:10090">mouse</span>
###xml 2628 2633 <span type="species:ncbi:10090">mouse</span>
###xml 2723 2728 <span type="species:ncbi:10090">mouse</span>
###xml 2791 2796 <span type="species:ncbi:10090">mouse</span>
###xml 2858 2863 <span type="species:ncbi:10090">mouse</span>
Effects of lysine 532 mutation in HIF-1alpha. A) HIF-1alpha protein levels were determined by Western blot analysis. B16F10-mock, B16F10-mARD1A225, and B16F10-mARD1A225-HIF-1alpha/K532R cells were cultured in the absence (N) or presence of 200 muM CoCl2 for 24 hours (24H). Similar results were obtained with three independent experiments. B) VEGFA levels (in picograms per milliliter) were quantified using enzyme-linked immunosorbent assay. B16F10, B16F10-mock, B16F10-mARD1A225, and B16F10-mARD1A225-HIF-1alpha/K532R cells were cultured in the absence (N) or presence of 200 muM CoCl2 for 4 hours (4H). Three independent experiments were performed, each in two replicates. Results are means and 95% confidence intervals (error bars) derived from the means of the individual experiments (n = 3). *P = .05 for all comparisons as determined with the two-sided Mann-Whitney U test. C) B16F10, B16F10-mock, B16F10-mARD1A225, and B16F10-mARD1A225-HIF-1alpha/K532R cells were grown to 80% confluence. A linear injury line was created at the center of the cultured monolayer by scraping with a sterile pipette tip. Cells were incubated in the presence of 200 muM CoCl2 for 24 hours. B16F10, B16F10-mock, and B16F10-mARD1A225-HIF-1alpha/K532R cells were treated with 3 mug/mL anti-mouse VEGFA antibody. B16F10-mARD1A225 cells were treated with 25 ng/mL recombinant mouse VEGFA protein. Images of cell migration (left). Quantification of cell migration (right). Migration distance (in micrometers); P = .004, determined with the two-sided Mann-Whitney U test. Three independent experiments were performed, each in two replicates. Results are means and 95% confidence intervals (error bars) derived from the means of the individual experiments (n = 3). Magnification x100. Scale bar = 100 mum. D) C57BL/6 mice were injected intravenously with B16F10-mock (n = 40 mice), B16F10-mARD1A225 (n = 31 mice) and B16F10-mARD1A225-HIF-1alpha/K532R cells (n = 11 mice). Lung nodule formation was determined 14 days after injection. Representative gross images of lungs are shown (left). Numbers of surface tumor nodules per mouse (right). Results are means and 95% confidence intervals (error bars). *P < .001, compared with the number of surface tumor nodules in B16F10-mock-injected mice, #P < .001, compared with the number of surface tumor nodules in B16F10-mARD1A225-injected mice, as determined with the two-sided Mann-Whitney U test. A#1 = B16F10-mARD1A225 #1; A#2 = B16F10-mARD1A225 #2; A#1/HIF K532R = B16F10-mARD1A225 #1-HIF-1alpha/K532R; B16F10 + anti-VEGFA = B16F10 + anti-mouse VEGFA antibody; Mock + anti-VEGFA = B16F10-Mock + anti-mouse VEGFA antibody; A#1/HIF K532R + anti-VEGFA = B16F10-mARD1A225 #1-HIF-1alpha/K532R + anti-mouse VEGFA antibody; A#1+VEGFA = B16F10-mARD1A225 #1 + recombinant mouse VEGFA protein; A#2+VEGFA = B16F10-mARD1A225 #2 + recombinant mouse VEGFA protein.
###end p 97
###begin p 98
###xml 135 143 131 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8</xref>
###xml 200 203 196 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 499 502 487 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 559 562 547 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 718 721 702 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 780 783 764 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 847 848 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 877 885 857 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8</xref>
To confirm the functional consequences of HIF-1alpha overexpression, we measured VEGFA levels in the conditioned media of these cells (Figure 8, B). After 4 hours of hypoxia, VEGFA secretion by mARD1A225-HIF-1alpha/K532R-expressing cells was statistically significantly higher than that of mock-infected or parental cell lines, implying a critical role for lysine 532 in the regulation of HIF-1alpha stability (normoxic condition: B16F10/mock, mean = 50 pg/mg, 95% CI = 24.53 to 75.47; B16F10/mARD1A225 #1, mean = 2.08 pg/mg, 95% CI = 0 to 6.16; B16F10/mARD1A225/HIF-1alpha/K532R, mean = 58.33 pg/mg, 95% CI = 22.74 to 93.92; hypoxic condition: B16F10/mock, mean = 447.91 pg/mg, 95% CI = 401.9 to 493.92; B16F10/mARD1A225 #1, mean = 337.5 pg/mg, 95% CI = 288 to 387; B16F10/mARD1A225/HIF-1alpha/K532R, mean = 654.2 pg/mg, 95% CI = 509.9 to 798.5; P < .05 for all comparisons) (Figure 8, B).
###end p 98
###begin p 99
###xml 204 207 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 297 305 293 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8</xref>
###xml 555 558 551 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 614 617 610 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 726 729 720 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 809 810 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 962 965 950 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 997 1000 985 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1037 1040 1021 1024 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1121 1122 1103 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1319 1322 1301 1304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1405 1408 1383 1386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1445 1448 1419 1422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1558 1559 1526 1527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1600 1603 1568 1571 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1624 1627 1592 1595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1647 1650 1615 1618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1760 1763 1726 1729 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1783 1786 1749 1752 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1886 1887 1849 1850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1916 1924 1879 1887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8</xref>
###xml 2009 2012 1972 1975 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1222 1227 <span type="species:ncbi:10090">mouse</span>
###xml 1258 1263 <span type="species:ncbi:10090">mouse</span>
VEGFA is an important endothelial mitogen but has also been reported to induce migration in a number of cell types, including tumor cells. Accordingly, we examined the ability of VEGFA generated by mARD1A225-HIF-1alpha/K532R-expressing tumor cells to potentiate cell migration in a scratch assay (Figure 8, C). A linear injury line was created at the center of a tissue culture dish, and tumor cell migration examined after 24 hours of incubation under hypoxic conditions. Regrowth and migration of B16F10 cells from the wound edge was inhibited by mARD1A225 (cell migration distances, B16F10/mock vs B16F10/mARD1A225 #1, mean = 591.4 vs 146.6 mum, difference = 444.8 mum, 95% CI = 429.4 to 460.3; B16F10/mock vs B16F10/mARD1A225 #2, mean = 591.4 vs 94.7 mum, difference = 497.7 mum, 95% CI = 488.1 to 505.4; P = .004 for all comparisons). As expected, increased expression of VEGFA in mutant HIF-1alpha/K532R cells led to enhanced migration compared with mARD1A225-expressing cells (B16F10/mARD1A225 #1-HIF-1alpha/K532R vs B16F10/mARD1A225 #1, mean = 611.9 vs 146.6 mum, difference = 465.3 mum, 95% CI = 462.5 to 468.2; P = .004). To confirm the specificity of VEGFA-mediated cell migration, we added a neutralizing anti-mouse VEGFA antibody or recombinant mouse VEGFA protein, which suppressed the migration of mARD1A225-HIF-1alpha/K532R-expressing tumor cells into the linear injury line (B16F10/mARD1A225 #1-HIF-1alpha/K532R vs B16F10-mARD1A225 #1-HIF-1alpha/K532R + anti-VEGFA, mean = 611.9 vs 219.5mum, difference = 392.4 mum, 95% CI = 379.2 to 405.7; P = .004) but enhanced migration of mARD1A225 cells (B16F10/mARD1A225 #1 vs B16F10-mARD1A225 #1 + VEGFA protein, mean = 146.6 vs 771.8 mum, difference = 625.2 mum, 95% CI = 616.8 to 633.6; B16F10/mARD1A225 #2 vs B16F10-mARD1A225 #2 + VEGFA protein, mean = 94.7 mum vs 652.2 mum, difference = 557.5 mum, 95% CI = 534.8 to 580.3; P = .004 for all comparisons; Figure 8, C). The data clearly suggest that reduction of VEGFA is a critical factor in mARD1A225-induced inhibition of B16F10 cell migration.
###end p 99
###begin p 100
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 184 187 180 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 215 218 211 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 362 365 354 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 443 446 431 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 516 519 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 536 539 524 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 618 621 602 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 682 685 666 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 702 705 686 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 768 769 748 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 798 806 778 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8</xref>
###xml 1222 1225 1190 1193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 330 334 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 481 486 <span type="species:ncbi:10090">mouse</span>
To determine the in vivo effects of the mARD1A225-HIF-1alpha/K532R mutants, we examined the formation of lung nodules after intravenous injection of B16F10-mock (n = 40), B16F10-mARD1A225 (n = 31), and B16F10-mARD1A225-HIF-1alpha/K532R (n = 11) cells into syngeneic C57BL/6 mice. The number of surface tumor nodules was higher in mice injected with B16F10-mARD1A225-HIF-1alpha/K532R cells compared with that in mice injected with B16F10-mARD1A225 cells (number of lung nodules per mouse: B16F10/mock vs B16F10/mARD1A225 vs B16F10/mARD1A225/HIF-1alpha/K532R, mean = 217.1 vs 16.38 vs 111.8; B16F10/mock vs B16F10/mARD1A225, difference = 200.72, 95% CI = 169.4 to 232.2; B16F10/mARD1A225 vs B16F10/mARD1A225/HIF-1alpha/K532R, difference = 95.42, 95% CI = 57.4 to 133.4; P < .001 for all comparisons; Figure 8, D). We tested the activity of a mutant HIF-1alpha/K532R, which was stably expressed under normoxic conditions (see , , available online). Increased expression of mutant HIF-1alpha/K532R in B16F10-mock cells led to enhanced migration and metastasis compared with B16F10-mock-mock cells (see ,  and , available online). Therefore, stabilization of HIF-1alpha appears to reverse the tumor-suppressive effect of mARD1A225 on lung lesions. Based on these data, we propose that lysine 532 of HIF-1alpha is important for HIF-1alpha degradation, ultimately leading to the regulation of VEGFA expression.
###end p 100
###begin title 101
Discussion
###end title 101
###begin p 102
###xml 58 61 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 209 212 205 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 356 362 <span type="species:ncbi:10090">murine</span>
###xml 367 372 <span type="species:ncbi:9606">human</span>
We demonstrate that the potent antitumor effects of mARD1A225 are mediated by HIF-1alpha degradation, resulting in reduced expression of its well-characterized target, VEGFA. Moreover, overexpression of mARD1A225 leads to inhibition of tumorigenesis in three different tumor models via reduction of VEGFA expression and its proangiogenic functions in both murine and human cancer cells.
###end p 102
###begin p 103
###xml 7 12 7 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 214 217 214 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APC</italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 326 331 326 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 529 534 529 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 660 665 660 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 733 738 733 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 828 831 828 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 1022 1025 1022 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">716</sup>
###xml 1218 1220 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 1301 1306 1301 1306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 1313 1316 1313 1316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1465 1468 1465 1468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1544 1549 1544 1549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Min/+</sup>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 245 250 <span type="species:ncbi:9606">human</span>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
###xml 535 539 <span type="species:ncbi:10090">mice</span>
###xml 739 744 <span type="species:ncbi:10090">mouse</span>
###xml 751 756 <span type="species:ncbi:10090">mouse</span>
###xml 983 988 <span type="species:ncbi:10090">mouse</span>
###xml 1317 1332 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1550 1555 <span type="species:ncbi:10090">mouse</span>
The ApcMin/+ mice have been widely used as a model for studying early events in intestinal tumorigenesis. Recent reports indicate that VEGFA expression was increased and correlated with adenomatous polyposis coli (APC) gene mutations in primary human colon tumors (19). Also, this model showed that short-term treatment of ApcMin/+ mice with an anti-VEGFA monoclonal antibody results in reduced tumor burden and vessel density of intestinal polyps (21). Similarly, targeted deletion of VEGFA in intestinal epithelial cells of ApcMin/+ mice induced a statistically significant reduction in tumor growth (21), suggesting that VEGFA plays an important role in ApcMin/+ intestinal polyp growth. The offspring from a cross between the ApcMin/+ mouse and a mouse null for the endogenous anti-angiogenic protein thrombospondin 1 (THBS1-/-) showed a significant increase in polyp number and diameter (22), indicating a possible role for angiogenesis in polyp development. A study of another mouse model of intestinal adenomas, Apc716, which reported elevated VEGFA protein levels in polyps compared with normal intestinal epithelium control tissue, was also consistent with an association between VEGFA and polyp development (23). In our experiments, VEGFA expression was decreased in intestinal polyps of ApcMin/+/mARD1A225 transgenic mice, which, in turn, led to suppression of tumor growth and angiogenesis. Therefore, we propose that transgenic overexpression of mARD1A225 exerts an important tumor-suppressive effect via inhibition of VEGFA in ApcMin/+ mouse intestinal polyps.
###end p 103
###begin p 104
###xml 51 53 51 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 160 162 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 208 211 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 515 518 507 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 645 648 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 721 724 709 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 974 977 958 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 220 225 <span type="species:ncbi:9606">human</span>
###xml 245 250 <span type="species:ncbi:10090">mouse</span>
Whereas the vast majority of tumors express VEGFA (24), it is clear that VEGFA regulation by HIF-1alpha plays a critical role in tumor angiogenesis and growth (25). Here, we show that overexpression of mARD1A225 in both human gastric cancer and mouse melanoma cells induces a statistically significant reduction of HIF-1alpha protein expression and consequent production of VEGFA. Furthermore, the growth of lung nodules in an experimental model of lung metastases was markedly inhibited by overexpression of mARD1A225 in cancer cells. Expression of HIF-1alpha and VEGFA triggered under conditions of intratumoral hypoxia was decreased by mARD1A225 in B16F10 and MKN74 tumors. Our in vitro studies demonstrate that mARD1A225 overexpression leads to suppression of VEGFA-mediated endothelial cell proliferation, migration, and capillary tube formation. The data collectively suggest that the decrease in VEGFA levels induced as a result of degradation of HIF-1alpha by mARD1A225 inhibits tumor growth and angiogenesis in vivo.
###end p 104
###begin p 105
###xml 199 202 191 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 463 466 439 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 589 592 565 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 664 672 640 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8</xref>
###xml 725 728 701 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1039 1042 1007 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 1213 1215 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 1216 1218 1180 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 1082 1087 <span type="species:ncbi:9606">human</span>
###xml 1176 1181 <span type="species:ncbi:9606">human</span>
This study confirms the in vivo importance of a single lysine residue in regulating the stability of HIF-1alpha. To our knowledge, HIF-1alpha is the only known target of the acetyltransferase, mARD1A225. Our analyses of the mutant HIF-1alpha construct, HIF-1alpha/K532R, show that VEGFA overexpression is because of the stability of HIF-1alpha. However, the effects of the mutant HIF-1alpha in tumor cells did not fully override the increased expression of mARD1A225, such that the incidence of lung tumor lesions in our experimental model of lung metastases was higher than that in mARD1A225-overexpressing cells but not higher than in mock-infected tumor cells (Figure 8, D). This suggests that additional targets of mARD1A225 are involved in regulating tumor growth and/or progression. Other limitations of this study are that we only examined VEGFA expression as a measure of HIF-1alpha activity. We also could not exclude the possibility of other HIF-1alpha-targets involved in tumor growth and/or progression. In addition, the mARD1A225 isoform has not yet been identified in human cell lines. However, recent reports provide direct evidence for an inhibitory effect of human ARD1A on HIF-1alpha stability (26,27).
###end p 105
###begin p 106
###xml 54 57 54 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 185 188 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
###xml 347 350 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">225</sup>
Our data collectively confirm the importance of mARD1A225 in regulating tumor growth and development and provide evidence of its antitumor and antiangiogenic activities. Notably, mARD1A225 regulates tumor growth via degradation of HIF-1alpha and consequent reduced expression of the proangiogenic protein, VEGFA. Therefore, we conclude that mARD1A225 presents a novel target in the regulation of HIF-1alpha stability and may have potent therapeutic effects in combination with currently approved anti-VEGFA treatments such as bevacizumab.
###end p 106
###begin title 107
Funding
###end title 107
###begin p 108
###xml 66 103 66 103 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Research Foundation of Korea</funding-source>
###xml 130 180 130 180 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ministry of Education, Science &amp; Technology (MEST)</funding-source>
###xml 231 249 231 249 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R16-2004-001010010</award-id>
###xml 269 315 269 315 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Research program for New Drug Target Discovery</funding-source>
###xml 317 343 317 343 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M108KB010014-08K0201-01420</award-id>
###xml 33 38 <span type="species:ncbi:9606">Human</span>
21st Century Frontier Functional Human Genome Project (FG06-2-9); National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, Science & Technology (MEST) through the Creative Research Initiative Program (R16-2004-001010010 to K.-W.K., 2009); Research program for New Drug Target Discovery (M108KB010014-08K0201-01420) grant from MEST.
###end p 108
###begin title 109
Supplementary Material
###end title 109
###begin title 110
[Supplementary Data]
###end title 110
###begin article-title 111
###xml 98 103 <span type="species:ncbi:4932">yeast</span>
Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast
###end article-title 111
###begin article-title 112
###xml 64 88 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
N alpha acetylation is required for normal growth and mating of Saccharomyces cerevisiae
###end article-title 112
###begin article-title 113
###xml 4 9 <span type="species:ncbi:4932">yeast</span>
The yeast ARD1 gene product is required for repression of cryptic mating-type information at the HML locus
###end article-title 113
###begin article-title 114
###xml 17 22 <span type="species:ncbi:4932">yeast</span>
The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways
###end article-title 114
###begin article-title 115
Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation
###end article-title 115
###begin article-title 116
Characterization of ARD1 variants in mammalian cells
###end article-title 116
###begin article-title 117
Targeting HIF-1 for cancer therapy
###end article-title 117
###begin article-title 118
Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation
###end article-title 118
###begin article-title 119
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation
###end article-title 119
###begin article-title 120
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing
###end article-title 120
###begin article-title 121
Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway
###end article-title 121
###begin article-title 122
Role of angiogenesis in tumor growth and metastasis
###end article-title 122
###begin article-title 123
Angiogenesis in cancer and other diseases
###end article-title 123
###begin article-title 124
Tumor angiogenesis
###end article-title 124
###begin article-title 125
Angiogenesis and metastasis
###end article-title 125
###begin article-title 126
###xml 38 43 <span type="species:ncbi:9606">human</span>
Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications
###end article-title 126
###begin article-title 127
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
###end article-title 127
###begin article-title 128
###xml 90 95 <span type="species:ncbi:9606">human</span>
Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma
###end article-title 128
###begin article-title 129
beta-Catenin regulates vascular endothelial growth factor expression in colon cancer
###end article-title 129
###begin article-title 130
Tumor angiogenesis: therapeutic implications
###end article-title 130
###begin article-title 131
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice
###end article-title 131
###begin article-title 132
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
Thrombospondin 1-a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model
###end article-title 132
###begin article-title 133
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
###end article-title 133
###begin article-title 134
Vascular permeability factor (VPF, VEGF) in tumor biology
###end article-title 134
###begin article-title 135
Vascular endothelial growth factor (VEGF) signaling in tumor progression
###end article-title 135
###begin article-title 136
Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1
###end article-title 136
###begin article-title 137
Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis
###end article-title 137
###begin p 138
The funders did not have any involvement in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.
###end p 138
###begin p 139
We gratefully acknowledge the technical assistance of So-Young Kwon. We thank Dr Seongho Ryu in Cornell Medical School for advice on statistical analysis.
###end p 139

